sign in sign up
<<
Home , AATK, Aleglitazar, Fasting, GPR119, Lobeglitazone, Myokine

SUBJECT INDEX

(-)-Epigallocatechin-3-gallate 2919-PO Add-on to basal 1102-P Aggressiveness factor 2526-PO 1,5-Anhydroglucitol 928-P Add-on to 1092-P Aging 1284-P, 1396-P, 1399-P, 1797-P, 1966-P, 11 β-HSD 1993-P Add-on to metformin + SU 1082-P 1972-P, 1981-P, 2007-P, 2209-P, 2308-PO, 11beta-HSD, glucocorticosteroids, type 2 Add-on to 1120-P 2481-PO, 2693-PO, 2697-PO 1128-P Adenine nucleotide 28-OR, 29-OR Aging society 2657-PO 11β-HSD1 1875-P Adenosine A1 1854-P Agreement 2508-PO SUBJECT INDEX 12(S)-HETE 2057-P Adenovirus, shrna, over expression 340-OR Agrp neurons 1917-P 12/15-Lipoxygenase 2057-P Adherence 652-P, 789-P, 802-P, 814-P, 821-P, 857-P, AICAR 1815-P 12-Lipoxygenase 338-OR 889-P, 894-P, 1227-P, 1259-P, 1423-P, 2504-PO Akita 1643-P 14-3-3 142-OR Adhesive capsulitis 2887-PO Akt 25-OR 18FDG PET 2026-P Adipocyte 100-OR, 1644-P, 1748-P, 1748-P, 1749-P, Akt mediated signaling pathway 2321-PO 18F-TTCO-cys40-exendin-4 2163-P 1751-P, 1752-P, 1755-P, 1756-P, 1758-P, 1761-P, Akt, glucose uptake 1802-P 1-h plasma glucose 1457-P, 2808-PO 1763-P, 1765-P, 1769-P, 1769-P, 2056-P, 2943-PO Akt/GSK3 signaling pathway 488-P 25(OH)D 679-P Adipocyte differentiation 144-OR, 1745-P, 1745-P, Akt2 1818-P 25-hydroxivitamin D 2035-P 2013-P Alanine 1916-P 26S Proteasomes 498-P Adipocyte fatty acid-binding 2003-P Alanine aminotransferase 1460-P, 2860-PO 2-Aminobicyclo-(2,2,1)-heptane-2-carboxylic acid Adipocyte precursor cells 2081-P Alaska native people 183-OR 2079-P Adipocytes 94-OR, 95-OR, 1750-P 68-OR, 1010-P, 1044-P, 2590-PO 2-hour plasma glucose 1399-P Adipocytokines 1753-P, 2338-PO Albumin to creatinine ratio 2722-PO 3D microscopy 361-OR Adipogenesis 142-OR, 302-OR, 1752-P, 1763-P, Albuminuria 103-OR, 108-OR, 417-P, 419-P, 472-P, 3-hydroxybutyrate 2521-PO 2069-P, 2074-P, 2086-P, 2113-P 520-P, 555-P, 557-P, 559-P, 572-P, 719-P, 719-P, 3T3-L1 2921-PO Adipokine 1296-P, 1331-P, 1386-P, 2109-P, 2109-P, 1293-P, 1293-P, 1307-P, 1523-P, 2377-PO, 4-1BB 1719-P 2677-PO, 2686-PO 2387-PO, 2629-PO, 2725-PO 6q24 129-OR Adiponectin 202-OR, 250-OR, 446-P, 474-P, 624-P, consumption 2267-P 7-point profile 906-P 650-P, 761-P, 1356-P, 1463-P, 1467-P, 1506-P, Aldose reductase inhibitor 577-P 9p21 locus 1505-P 1610-P, 1884-P, 2092-P, 2131-P, 2209-P, 2591-PO Aldosterone 566-P, 762-P, 2000-P A meta-analysis 1521-P Adiponectin multimer 741-P 1142-P A1C 861-P, 877-P, 900-P, 1152-P, 1474-P, 1487-P, Adiponectin receptor 1807-P Aliskiren 566-P, 1191-P 1497-P, 1516-P, 1640-P, 2542-PO Adipor 64-OR, 202-OR All-cause mortality 278-OR A1c registry 2-OR Adipose 1637-P, 1743-P, 2102-P, 2102-P Alloreactive T cells 287-OR AATK 195-OR 63-OR, 168-OR, 1744-P, 1803-P, All-trans retinoic acid 2907-PO Abdominal 1909-P 1812-P, 1951-P, 2105-P, 2105-P, 2110-P, 2159-P 1143-P, 2621-PO, 2647-PO Abnormal glucose tolerance 1466-P Adipose tissue browning 1917-P Alpha cell 1053-P, 2851-PO Abnormal glycorgulation 1492-P Adipose tissue 99-OR Alpha glucosidase inhibitors 2628-PO Aboriginal 1535-P Adipose tissue 2104-P Alpha lipoic acid 592-P, 2923-PO Acabose 2626-PO Adipose tissue restriction 1856-P Alpha-1-microglobulin 2375-PO Academics 1349-P Adipose tissue secretion 2095-P Alpha-glucosidase inhibitor 2150-P Acanthosis nigricans 2677-PO Adiposity 2042-P Alphatc1-9 2286-P 2150-P Administrative claims 1426-P Alternative splicing 1759-P ACC2 1776-P Administrative database 1268-P, 2306-PO Alzheimer’s 595-P, 600-P, 1181-P Access to 755-P Admission glucose 2766-PO Ambulatory blood pressure 550-P ACCORD 207-OR, 709-P, 1065-P Admission 478-P American indian 1666-P, 2465-PO Accuracy 391-P, 873-P, 874-P, 899-P, 904-P Admissions avoidance 1248-P Amino acid 1125-P, 1451-P ACE insertion/deletion polymorphism Adolescents 82-OR, 734-P, 789-P, 790-P, 791-P, Ammonia 1916-P 2331-PO 824-P, 827-P, 835-P, 847-P, 1291-P, 1293-P, AMPK 34-OR, 36-OR, 253-OR, 254-OR, 1050-P, ACE2 719-P, 2291-P 1307-P, 1314-P, 1324-P, 1327-P, 1337-P, 1342-P, 1814-P, 1815-P, 1876-P, 1893-P, 1895-P, 1916-P, Acetyl coa inhibition 636-P 1349-P, 1352-P, 2407-PO, 2504-PO, 2673-PO, 1940-P, 1941-P, 1966-P, 2050-P Acetylation 28-OR 2874-PO Amputation 118-OR, 120-OR, 672-P, 672-P, 2437-PO, 2283-P Adrenergic signaling 1810-P 2439-PO Acetyl-coa carboxylase (ACC) β 519-P Adults 842-P, 808-P Amygdala 2053-P Actin 1756-P Advanced diabetic nephropathy 548-P 2167-P Actin cytoskeleton 2075-P Advanced glycation end products 57-OR, 104-OR, Amyloid 300-OR Action potential 599-P 205-OR, 426-P, 1208-P, 1333-P, 1348-P, 1920-P, Anabolic 616-P Active comparator 238-OR 1937-P, 2409-PO, 2738-PO Ancestry 86-OR, 1540-P Acute complications 2788-PO Advanced practice nurse 318-OR Androgen receptor 2226-P Acute coronary syndrome 349-OR, 459-P, 478-P, Advanced 70-OR Angiogenesis 576-P, 610-P, 668-P, 668-P, 1726-P, 1253-P, 1415-P Adverse event 275-OR 2077-P, 2469-PO Acute inflammatory response 1627-P Adverse outcomes 1270-P Angiogrography 2436-PO Acute insulin response 1652-P Aerobic 216-OR, 1890-P Angiotensin 1-7 1964-P Acute phase reactants 421-P Africa 1485-P, 2786-PO Angiotensin II 1854-P, 2910-PO Acute stroke 2711-PO African american 217-OR, 322-OR, 2099-P Angiotensin receptor blocker 1804-P ADAM17 and ACE2 shedding 2367-PO African american women 182-OR, 706-P Animal model 2843-PO, 2922-PO Adaptive control 2582-PO AG average glucose 2542-PO Ankle-brachial index 119-OR, 588-P Adaptive optics 154-OR Age 92-OR, 560-P, 625-P, 962-P, 1208-P, 1210-P, ANRIL 449-P ADCY5 1635-P 1397-P, 1519-P, 1597-P, 2415-PO Ansiscope 2402-PO Addition study 2721-PO AGE reader 1519-P Anti CD3 antibody 1705-P Additivity 909-P Age related macular degeneration 2409-PO Antibiotic eradication 192-OR

OR-Oral P-Poster PO-Published Only A755 Antibody 1687-P Audit impact 2671-PO 2213-P, 2235-P, 2263-P, 2263-P, 2266-P, Anticancer agent 2767-PO Autoantibodies 128-OR, 1611-P, 1839-P 2271-P,2278-P, 2282-P, 2292-P, 2294-P, 2294B-P, Antidiabetic 209-OR Autoantigen 1700-P 2520-PO, 2823-PO, 2851-PO, 2968-PO Antihyperglycemic agents 1030-P Autoimmune 246-OR, 1626-P Beta cell apoptosis 199-OR, 336-OR, 2162-P, 2171-P Anti-inflammation 377-OR, 1678-P, 1703-P, 2052-P Autoimmune regulator (AIRE) 1692-P Beta cell biology 2244-P Anti-obesity 2052-P Autoimmunity 19-OR, 282-OR, 1207-P, 1475-P, Beta cell compensation 2219-P Anti-oxidant 1078-P, 1740-P, 2170-P, 2977-PO 1714-P, 2166-P, 2431-PO Beta cell dysfunction 335-OR, 1578-P, 1832-P Antioxidant defense 607-P Autoislets 362-OR Beta cell function 80-OR, 163-OR, 199-OR, Antipsychotic 150-OR, 317-OR, 2138-P Automated insulin delivery 228-OR 427-P,954-P, 981-P, 1028-P, 1117-P, 1138-P, SUBJECT INDEX Anxa1 2967-PO Automatic messages 867-P 1292-P, 1292-P, 1402-P, 1402-P, 1462-P, 1492-P, Anxiety 775-P, 787-P, 844-P Automatic suspension 974-P 1547-P, 1688-P, 1825-P, 1828-P, 1829-P, 1835-P, Aortic stiffness 1413-P, 2328-PO Autonomic neuropathy 53-OR, 131-OR, 593-P, 1838-P, 1842-P, 2153-P, 2185-P, 2228-P, 2284-P, Apnea hypopnea index 1302-P 2395-PO 2697-PO, 2717-PO,2847-PO Apo a-I 2249-P 60-OR, 512-P, 539-P, 1784-P, 1801-P, Beta cell mass 44-OR, 46-OR, 195-OR, 341-OR, Apoe polymorphism 637-P 1864-P, 1915-P, 2178-P, 2183-P, 2336-PO, 2803-PO 2258-P, 2915-PO Apolipoprotein A-I 303-OR Autoreactive T cells 288-OR Beta cell preservation 2572-PO Apolipoprotein B 355-OR, 659-P, 2422-PO Avanafil 585-P Beta cell proliferation 46-OR, 1686-P, 2193-P, Apoptosis 203-OR, 288-OR, 492-P, 502-P, 590-P, Avandamet 2639-PO 2200-P 1795-P, 2093-P, 2165-P, 2170-P, 2172-P, 2176-P, Average plasma glucose 2532-PO Beta cell protection 110-OR, 338-OR 2187-P, 2292-P Azelnidipine 1204-P Beta cell regeneration 1729-P, 2040-P, 2634-PO, Appetite regulation 2106-P B lymphocyte 291-OR 2642-PO, 2966-PO APPL1 2182-P B12 1062-P, 1068-P Beta cell rest 2236-P Appointment adherence 1240-P B7.1 523-P Beta cell secretory capacity 1109-P Aquaporin-2 532-P B7-H4 1694-P, 1696-P Beta cell specific ATGL knockout mice 2194-P Arabs 2723-PO Baratric 1-OR, 103-OR, 155-OR, 190-OR, Beta cell specific syntaxin-1A KO mice 2220-P ARC 340-OR 554-P, 628-P, 1842-P, 1927-P, 1954-P, 2018-P, Beta cell survival 194-OR, 2180-P, 2234-P Archimedes model 1573-P, 2339-PO 2088-P, 2098-P, 2098-P, 2101-P, 2101-P, 2114-P, Beta cell targeting agent 198-OR Areca 1536-P 2115-P, 2116-P, 2119-P, 2139-P, 2142-P, 2143-P, Beta cell, Pdx1, Hnf6 43-OR Arg913Gln(G A)variation 2385-PO 2147-P, 2148-P, 2153-P, 2154-P, 2155-P, 2426-PO, BETA2/neurod 2216-P Arrhythmias 233-OR 2868-PO, 2871-PO, 2873-PO, 2913-PO, 2931-PO, Betacatenin 1872-P Arterial stiffness 471-P, 1525-P, 1525-P, 2332-PO, 2935-PO, 2937-PO Betaine 2867-PO 2348-PO, 2355-PO, 2357-PO, 2956-PO Barriers to care 714-P Beta-klotho 2006-P Artery 493-P Barriers to participation in clinical trial 816-P BI-1 1724-P Artificial 9-OR, 10-OR, 11-OR, 14-OR, Basal bolus insulin 260-OR Bid 2181-P 15-OR, 16-OR, 171-OR, 404-P, 967-P, 967-P, Basal bolus therapy 2567-PO, 2575-PO 1171-P 973-P, 977-P, 991-P, 993-P, 999-P, 1015-P, 2002-P, Basal insulin 888-P, 936-P, 952-P, 961-P, 1018-P, Bile acids 1170-P, 1860-P, 1860-P, 2018-P, 2089-P, 2526-PO, 2577-PO, 2582-PO, 2586-PO 1029-P, 1084-P, 2551-PO, 2553-PO, 2555-PO, 2894-PO Artificial pancreas / bionic pancreas 2556-PO, 2564-PO, 2596-PO, 2622-PO Bim Puma 336-OR AS160 phosphorylation 1800-P Basal insulin secretion 1848-P Biochemical autoantibody screening 2703-PO Ashkenazi 1657-P Basal insulin therapy 2581-PO, 2585-PO Bioengineered pancreas 1726-P Asian 1159-P, 1177-P, 1233-P, 1397-P, 1451-P, Basal-bolus 256-OR, 896-P Biomarkers 247-OR, 528-P, 544-P, 1698-P, 1716-P, 1486-P Basal-Plus 1021-P 1824-P, 2072-P, 2260-P, 2347-PO, 2378-PO, Asian Indian 1462-P Basement membrane 517-P 2520-PO ASPIRE Study 971-P Bauhinia forficata 2977-PO Biomarkers for inflammation 2764-PO ASPIRE-2 984-P Bazedoxifene 2652-PO Bionic pancreas 15-OR Aspirin 425-P, 1430-P B-cell compensation 1849-P, 2064-P Biopsy 605-P, 1689-P Association 547-P, 1396-P B-cell function 1843-P, 2620-PO Biphasic 30 2563-PO, 2565-PO Association resource (KARE) study 2803-PO B-cell mass 1843-P Bipolar disorder 2517-PO Association study 629-P, 1622-P B-cell phenotype 2285-P Birth certificate 181-OR Astaxanthin 1865-P B-cells 2283-P Birth weight 1296-P, 1543-P, 1583-P Astrocyte 838-P, 1919-P BDNF polymorphism 797-P Bisphenol A 1555-P Astrocytic dysfunction 609-P Behavior modification 2495-PO Bladder 1066-P, 2646-PO Asymmetric dimethylarginine 440-P Behavioral assessment, self-management support Blood flow 1933-P Asymptomaic ischemia 480-P 826-P Blood glucose 743-P, 880-P, 2473-PO Asymptomatic diabetic patient 433-P Behavioral change 858-P, 2453-PO Blood glucose assessment 874-P, 895-P, 899-P At high risk for diabetes 715-P Behavioral health 823-P, 837-P, 839-P Blood glucose concentration 2540-PO ATF3 538-P, 655-P, 2267-P Behavioral intervention 755-P, 813-P Blood glucose control 973-P ATGL 2062-P Behavioral lifestyle intervention 682-P Blood glucose economics 2660-PO Atherogenesis 505-P, 511-P, 663-P Behavioral medicine 779-P Blood glucose fluctuation 2408-PO Atherogenic dyslipidemia 1412-P Behavioral outcomes 778-P Blood glucose meter 2452-PO 21-OR, 201-OR, 202-OR, 203-OR, Behavioral risk factor survey (BRFS) 1507-P Blood glucose monitoring system 873-P, 904-P 205-OR, 417-P, 421-P, 424-P, 426-P, 438-P, 441-P, Behavior change 2445-PO Blood glucose self-monitoring 871-P 447-P, 449-P, 466-P, 483-P, 503-P, 515-P, 884-P, Beige adipocytes 2008-P, 2075-P Blood glucose variability 914-P 1209-P, 2353-PO Beliefs 2466-PO Blood ketones 2651-PO ATM 2279-P Benchmarking 806-P, 811-P Blood pressure 1077-P, 1410-P, 1581-P, 1592-P, 481-P Benefit-risk 1034-P 2151-P, 2384-PO, 2442-PO ATP 1914-P Beta 2 microglobulin 432-P Blood vessel 493-P Atrial fibrillation 1418-P Beta Cell 47-OR, 196-OR, 217-OR, 288-OR, 290-OR, BMI 77-OR, 1130-P, 1473-P, 1591-P, 2096-P, 2109-P, Attention deficit hyperactivity disorder 786-P 334-OR, 365-OR, 666-P, 956-P, 1023-P, 1691-P, 2964-PO Attributable risk 1542-P 2095-P, 2165-P, 2172-P, 2183-P, 2184-P, 2186-P, BNP 453-P Atypical C 2082-P 2187-P, 2192-P, 2199-P, 2201-P, 2203-P, 2206-P, Body composition 2101-P, 2480-PO, 2850-PO, 2946-PO

A756 OR-Oral P-Poster PO-Published Only Body fat 122-OR, 2964-PO Carbohydrate counting 315-OR, 691-P, 713-P, 767-P, CEACAM1 1778-P Body mass index 81-OR, 751-P, 1322-P, 1393-P, 885-P Ceamide 655-P 1491-P, 1665-P, 2103-P, 2689-PO Carbohydrates and glucose control 2882-PO Celiac disease 248-OR, 1347-P, 1517-P Body shape 1473-P Carboxylation 2005-P Cell apoptosis 2182-P Body size perception 2673-PO Cardiac arrest 463-P Cell cycle 2193-P Body weight 81-OR, 372-OR, 1064-P, 1182-P, 1491-P, Cardiac arrhythmias 235-OR Cell encapsulation 943-P 2043-P, 2150-P, 2654-PO Cardiac autonomic neuropathy 175-OR, 575-P, Cell proliferation 2967-PO Bolus advisor 872-P, 875-P, 877-P, 885-P, 889-P 583-P, 598-P, 2397-PO Cell surface markers 494-P Bolus calculation 894-P Cardiac baroreflex sensitivity 2010-P Cell therapy 678-P, 1737-P Bone 1524-P, 2791-PO Cardiac consequences in diabetic offspring 267-OR Cell transplantation 603-P SUBJECT INDEX Bone marrow 2918-PO Cardiac dysfunction 489-P Cellular efflux 638-P Bone metabolism 1030-P, 1071-P, 2631-PO Cardiac ischemia 508-P Central adiposity 486-P, 2735-PO Bone microstructure 664-P Cardiac progenitor cells 490-P Central regulation 333-OR, 1859-P, 2054-P Bone mineral density 1498-P Cardiac repolarization 1044-P Ceramide 339-OR, 555-P, 1771-P, 1795-P, 2088-P Bone morphogenetic 511-P, 2008-P Cardiac side effects 1127-P Cerebral circadian rhythm generator 1702-P Botswana 2468-PO Cardiac surgery 312-OR Cerebrospinal fluid 151-OR Brain 88-OR, 89-OR, 149-OR, 383-OR, 395-P, 794-P, Cardiometabolic risk 475-P, 1294-P, 1439-P, 2331-PO Cervical plaque 2329-PO 805-P, 1788-P Cardiomyopathy 431-P, 465-P, 491-P, 2076-P Cesarean delivery 1375-P Brain activation 152-OR Cardioprotection 1189-P CFTR 2225-P Brain ageing 423-P Cardiovascualr surgery diabetes 342-OR CFTRΔF508 mutation 2232-P Brain atrophy 49-OR Cardiovascular 276-OR, 376-OR, 470-P, 1414-P, CGM 170-OR, 171-OR, 172-OR, 176-OR, 374-OR, Brain glucose metabolism 392-P 2349-PO, 2358-PO 862-P, 865-P, 886-P, 890-P, 897-P, 1609-P, Brain metabolism 234-OR, 1997-P Cardiovascular autonomic dysfunction 396-P 2529-PO, 2541-PO, 2632-PO, 2643-PO, 2688-PO, Brain natriuretic 2394-PO Cardiovascular autonomic neuropathy 604-P 2692-PO Brain neuroglycopenia 235-OR Cardiovascular biomarkers 2423-PO Changes in bmiz 658-P Brain-derived neurotrophic factor 1663-P Cardiovascular complications 451-P, 477-P Changing profile 2740-PO 801-P Cardiovascular death 446-P Charcot 117-OR Breast cancer 1574-P Cardiovascular disease 184-OR, 277-OR, 278-OR, Charcot foot 2431-PO Breastfeeding 1579-P, 1594-P, 2747-PO 343-OR, 348-OR, 355-OR, 427-P, 445-P, 453-P, Charlson co morbidity index 1407-P Breath analysis 881-P, 957-P 476-P, 866-P, 1135-P, 1174-P, 1258-P, 1326-P, CHD 1425-P 1172-P, 1193-P 1326-P, 1342-P, 1400-P, 1400-P, 1403-P, 1404-P, Chemerin 703-P, 1746-P, 1746-P Brown adipocyte 1757-P 1404-P, 1405-P, 1406-P, 1411-P, 1417-P, 1423-P, 518-P, 1126-P Brown adipogenesis 145-OR 1426-P, 1430-P, 1437-P, 1602-P, 1845-P, 2325-PO, Chernobyl NPP accident 2775-PO 101-OR, 144-OR, 1927-P, 2345-PO Chicory seed extract 1167-P 2026-P, 2157-P Cardiovascular disease risk 79-OR, 1411-P, 2413-PO, Childhood obesity 788-P, 1288-P, 1304-P, 1377-P, Brown rice 773-P 2426-PO 2732-PO 1541-P, 1607-P, 2674-PO Browning of adipocytes 1942-P Cardiovascular events 416-P, 420-P, 458-P, 462-P, Childhood type 1 diabetes 1279-P, 1353-P, 1576-P, Browning of adipose tissue 99-OR, 2013-P 1192-P, 1408-P, 1494-P, 1494-P 1606-P, 2587-PO Buffering factors 1220-P Cardiovascular mortality 2355-PO Childhood type 2 diabetes 1576-P, 1606-P Burden 1256-P Cardiovascular outcomes 1420-P, 2339-PO Children 179-OR, 212-OR, 354-OR, 1313-P, 1609-P, C reactive protein 1627-P Cardiovascular rehospitalization 1415-P 1615-P C1q/TNF-related protein-9 (CTRP-9) 2152-P Cardiovascular risk factors 442-P, 443-P, 479-P, Children migrated 1619-P C57BL/6 38-OR 798-P, 1182-P, 1311-P, 1321-P, 1322-P, 1386-P, 246-OR, 849-P, 1553-P, 2658-PO, 2781-PO CAC 2337-PO 1531-P, 2137-P, 2338-PO, 2678-PO, 2702-PO Chinese 1466-P, 1510-P, 1515-P, 1522-P, 2416-PO, CAD 345-OR, 448-P, 2343-PO Caribbean 826-P 2804-PO Cadmium 1459-P, 1597-P Carotid atherosclerosis 469-P Chinese population Caffeine 2473-PO Carotid intima-media thickness 439-P, 486-P, 1437-P, Chitinase-3-like protein 1 1961-P Calcaneal quantitative ultrasound 2038-P 2935-PO Cholesterol 300-OR, 636-P, 663-P, 749-P, 1788-P, Calcified plaque 348-OR Case ascertainment methods 1541-P, 1607-P 2186-P Calcitonin 1071-P Case study 1169-P Cholesterol efflux 414-P Calcium 1635-P, 2214-P, 2251-P, 2256-P, 2294B-P, Catalase deficiency 1896-P Chrebp 1757-P, 1764-P 2791-PO Catheters 994-P 2493-PO Calcium dynamics 368-OR Causality 1250-P Chromogranin A 283-OR Calcium Influx 2242-P Caveolae 89-OR Chronic care model 815-P, 820-P Caloric restriction 763-P, 1533-P, 1827-P, Caveolin-1 1817-P Chronic co morbidity 1281-P 2874-PO CB1 337-OR Chronic complications 2434-PO, 2790-PO, 2792-PO CAM kinase 2 2251-P CBG 2536-PO Chronic disease 1407-P, 2752-PO 238-OR, 239-OR, 1069-P, 1075-P, C-cell pathology 1002-P Chronic FFA reduction 1943-P 1077-P, 1080-P, 1084-P, 1098-P, 1110-P, 1122-P, CCL2 520-P Chronic glycemia 2542-PO 1124-P, 1139-P, 1164-P, 1232-P CCL21 1723-P Chronic hyperglycemia 1477-P Canakinumab 444-P CCMR 2701-PO Chronic kidney disease 543-P, 1496-P, 1510-P, Cancer 281-OR, 385-OR, 944-P, 1067-P, 1067-P, CCR2 107-OR, 520-P 2384-PO, 2397-PO, 2708-PO, 2885-PO 1497-P, 1497-P, 1564-P, 1813-P, 2783-PO CCR2 antagonist 1126-P Chronic obstructive pulmonary disease 1571-P Cancer cachexia 1682-P CCTA 2343-PO Chronic renal failure 1200-P Cancer diabetes 1476-P CCX140 107-OR Chronotype 801-P Cancer initiating cells 2841-PO CD16 483-P, 2353-PO Chylomicron 298-OR, 299-OR, 646-P Canine 1767-P CD163 1703-P Cinnamon polyphenols 643-P CANVAS 1124-P CD36 2248-P, 2872-PO CIPII 968-P Capillary blood 2524-PO CD4 T cell 1690-P CIR 859-P Capillary zone electrophoresis 1489-P Cdc42 2249-P, 2268-P Circadian 367-OR, 2270-P, 2875-PO Carbohydrate 164-OR, 380-OR, 767-P Cdkal1 1760-P Circadian clock 144-OR, 1785-P, 1889-P, 2044-P

OR-Oral P-Poster PO-Published Only A757 Circadian rhythms 196-OR, 612-P, 1677-P, 1987-P Continuous glucose monitoring 11-OR, 15-OR, Cystic fibrosis 751-P, 2232-P C-Jun N-terminal kinase 500-P, 2235-P 171-OR, 173-OR, 177-OR, 843-P, 861-P, 863-P, Cystitis 1509-P CK-18 1873-P 864-P, 866-P, 876-P, 882-P, 884-P, 886-P, 887-P, Cytochrome c 2256-P CKD 1675-P 888-P, 891-P, 896-P, 898-P, 900-P, 902-P, 903-P, 284-OR, 293-OR, 1797-P, 1803-P, 2037-P, Claims data 1445-P 907-P, 908-P, 952-P, 970-P, 974-P, 1058-P, 1058-P, 2175-P Clarke error grid analysis 883-P 1301-P, 1345-P, 1391-P, 1733-P, 2314-PO, 1686-P, 1713-P, 2282-P, 2324-PO, 2373-PO Clinic setting 713-P 2335-PO, 2522-PO, 2527-PO, 2531-PO, 2535-PO, Cytotoxic T cell 1691-P Clinic visit rate 1479-P 2537-PO, 2543-PO, 2569-PO DAFNE 713-P Clinical care 1394-P Continuous subcutaneous insulin infusion 133-OR, Daily practice 994-P SUBJECT INDEX Clinical database 1614-P 717-P, 953-P, 972-P, 990-P, 2461-PO Dammarane-type triterpene 1140-P Clinical guidelines 685-P Conversation map (CM™) 304-OR Dance 2489-PO Clinical inertia 1222-P Cooked 535-P 236-OR, 242-OR, 1105-P, 1116-P, Clinical outcomes 2445-PO COPII 2243-P 1163-P, 1176-P, 1188-P, 2623-PO, 2641-PO Clinical practice 900-P, 963-P Cord blood glucose 75-OR Data mining 1338-P Clinical proteomics 2718-PO Cord blood stem cell 1022-P Database resource 2807-PO Clinical risk factors 2391-PO Corneal confocal microscopy 50-OR, 574-P, 574-P, Dawn phenomenon 174-OR, 1449-P Clinical trial 1099-P, 1170-P, 1226-P 584-P Db/db mice 1178-P, 2907-PO Clinical utility index (CUI) 931-P Coronary angiography 452-P, 472-P, 2347-PO DCCT/EDIC study 105-OR, 477-P Clock gene 196-OR, 612-P, 1677-P Coronary artery atherosclerosis 419-P Death 233-OR Clonal mosaic event 125-OR Coronary artery calcification 426-P, 448-P, 485-P, Decision support 1284-P Closed-loop 12-OR, 13-OR, 313-OR, 357-OR, 964-P, 2341-PO Deficiency 2204-P 967-P, 977-P, 993-P, 2576-PO, 2578-PO Coronary artery disease 347-OR, 455-P, 480-P, 487-P, Deficiency in diabetes 2763-PO CNS 2049-P 1419-P, 1429-P, 1434-P, 1467-P, 2320-PO, Degludec 945-P Coaching 7-OR 2356-PO 258-OR Coeliac disease 1330-P Coronary artery stenosis 1431-P Delayer 2592-PO Coffee 2778-PO Coronary calcium 1411-P Dementia 423-P, 1179-P Cofilin 1756-P Coronary heart disease 346-OR, 457-P, 461-P, 484-P Dendritic cells 1693-P Co-formulation 945-P Coronary stenoses 442-P, 2330-PO Dental pulp stem cells 603-P Cognition 87-OR, 257-OR, 383-OR, 656-P, 794-P, Correction factor 998-P Depression 676-P, 775-P, 787-P, 797-P, 798-P, 799-P, 805-P, 978-P, 1663-P, 2505-PO Corticosteroid administration 1389-P 808-P, 841-P, 844-P, 845-P, 1231-P, 1596-P, Cognitive decline 803-P, 1179-P 1993-P, 2954-PO 2511-PO, 2678-PO, 2777-PO Cognitive dysfunction 838-P Cost 264-OR, 1212-P, 1232-P, 1256-P, 1265-P, Depressive symptoms 182-OR, 784-P, 1544-P, Cognitive function 413-P, 1501-P, 1556-P, 2342-PO 1266-P, 1268-P, 1277-P, 1548-P, 1557-P, 2552-PO, 2727-PO Cognitive impairment 810-P, 2094-P 2656-PO, 2660-PO, 2661-PO, 2664-PO, 2665-PO Detemir 1903-P Cohort study 1526-P, 1527-P, 2554-PO Cost predictors 1239-P Development 43-OR, 1323-P Colchicine 1558-P Cost-effectiveness 263-OR, 1224-P, 1272-P Device 985-P, 2533-PO Cold exposure 2069-P, 2140-P Costimulatory pathways 229-OR, 287-OR Dexamethasone 27-OR Cold pressure test 2328-PO Counterregulation 389-P Diabetes and fasting during 2599-PO 379-OR, 1060-P, 1152-P, 1161-P Counter-regulatory 1005-P, 2618-PO Diabetes awareness 2454-PO Collaborative 1201-P, 1231-P County-level estimates 185-OR Diabetes burden 807-P Collagen matrix 2171-P C-peptide 136-OR, 1122-P, 1141-P, 1343-P, 1346-P, Diabetes care in underserved communities Colorectal cancer 2839-PO 1616-P, 1618-P, 1836-P, 1839-P, 1855-P, 2016-P, 2457-PO Combination 65-OR, 1115-P 2393-PO, 2717-PO Diabetes complications 105-OR, 1500-P Combination devices 970-P CPOE 699-P Diabetes consultations 2506-PO Combination of and metformin 1059-P Cravings 1149-P Diabetes control 2378-PO, 2584-PO, 2727-PO Combination therapy 1148-P, 1156-P, 1175-P, C-reactive protein 753-P Diabetes database 2568-PO, 2606-PO 1176-P Creatinine 535-P, 2299-PO Diabetes distress 783-P, 840-P, 2505-PO Communication 793-P, 815-P, 2506-PO Critical illness 1009-P Diabetes duration 935-P Community 308-OR, 687-P, 1261-P, 2556-PO, Critical ischemia 437-P Diabetes during pregnancy 2747-PO 2714-PO Critical limb ischemia 2356-PO Diabetes education 308-OR, 310-OR, 311-OR, 680-P, Comorbidities 1265-P, 1283-P, 2664-PO Critical-care 313-OR 699-P, 2443-PO, 2462-PO Comparative effectiveness 1213-P, 1400-P, 1428-P, Crosslaps 2035-P Diabetes enriched pedigrees 324-OR 2147-P, 2568-PO Cross-sectional survey 681-P Diabetes epidemiology 1586-P Comparator trial 873-P, 904-P CRP 1678-P Diabetes health disparities 306-OR Compensation 2169-P CSII 409-P, 969-P, 996-P, 2583-PO, 2584-PO, Diabetes in guatemala 1474-P Complement c1q 1467-P 2669-PO, 2687-PO, 2688-PO Diabetes in pregnancy 271-OR, 1364-P, 1382-P, Complement regulatory 1708-P CTGF 41-OR 1388-P Compliance 2441-PO CTL 1693-P Diabetes incidence 183-OR, 185-OR, 1455-P Complication 1519-P, 2816-PO CTLA4-Ig 523-P Diabetes knowledge 717-P Complications 234-OR, 533-P, 839-P, 1275-P, 1494-P, Culturally tailored education 306-OR 707-P, 716-P, 786-P, 852-P, 1495-P, 2401-PO, 2722-PO, 2729-PO, 2785-PO Culture 2510-PO 870-P, 2443-PO, 2455-PO, 2467-PO Composition of FFA 2492-PO Curcumin 2029-P, 2923-PO Diabetes mellitus 186-OR, 303-OR, 419-P, 436-P, COMT 2077-P Current perception threshold 597-P 440-P, 563-P, 665-P, 1049-P, 1066-P, 1486-P, Concentrated insulin 918-P Cutaneous blood flow 929-P 1518-P, 1681-P, 1681-P, 1766-P, 1908-P, 2032-P, Confidence limit 901-P CVRR 558-P 2350-PO, 2356-PO, 2704-PO, 2831-PO Congenital 1628-P Cyclin D1 2067-P Diabetes mellitus, type 2 871-P, 1855-P, 2414-PO, Congenital hyperinsulinism of infancy 2683-PO Cycloset 1172-P, 1193-P, 2039-P 2697-PO, 2800-PO Content analysis 835-P Cyclosporine 2255-P Diabetes nurse prescribing 1264-P Continuing medical education 709-P, 2448-PO Cynomolgus monkeys 2417-PO Diabetes outcomes 850-P Continuity of care 1329-P Cystatin C 436-P, 461-P, 563-P, 570-P, 604-P, 627-P, Diabetes prevention 3-OR, 305-OR, 682-P, 689-P, Continuous ambulatory peritoneal dialysis 887-P 2381-PO, 2428-PO 813-P, 816-P, 833-P, 1073-P, 1184-P, 1210-P,

A758 OR-Oral P-Poster PO-Published Only 1252-P, 1261-P, 1272-P, 1360-P, 1360-P, 1567-P, Diastolic blood pressure 241-OR Dynamic electrochemistry 880-P, 895-P, 899-P 2516-PO Diastolic dysfunction 2078-P Dynamic PET imaging in 1934-P Diabetes program design 2465-PO Diazoxide 229-OR Dysglycemia 1488-P, 1730-P, 2415-PO Diabetes quality measures 1223-P Didpeptidyl peptidase-4 504-P Dyslipidemia 646-P, 658-P, 1133-P, 1565-P, 2429-PO, Diabetes related distress 829-P, 2510-PO Diet 73-OR, 163-OR, 846-P, 1325-P, 1325-P, 2466-PO 2680-PO Diabetes related hospital admissions 1513-P Diet composition 770-P, 2742-PO Early diagnosis 2072-P Diabetes remission 2868-PO Diet intervention 773-P Early growth response gene-1 (Egr-1) 495-P Diabetes risk 1443-P, 1447-P, 1546-P, 1858-P Dietary adherence 1330-P Early initiation 2737-PO Diabetes screening 265-OR, 1440-P Dietary fat 162-OR, 295-OR Early intensive diabetes management 2794-PO Diabetes self-care 784-P, 834-P, 1324-P, 1324-P, Dietary fiber 748-P, 753-P, 764-P, 1525-P, 2906-PO Early mortality 2391-PO SUBJECT INDEX 2468-PO Dietary habits 2745-PO Early phase insulin secretion 2230-P Diabetes self-management support 308-OR, 695-P Dietary protein 162-OR Early renal damage 528-P Diabetes terminology 715-P Diet-induced obesity 1749-P, 1918-P, 2044-P, Early stage hepatic steatosis 2858-PO Diabetes, IGT 1401-P 2653-PO, 2915-PO Early type 2 diabetes 469-P Diabetes, remoteness, socioeconomic status Differential white blood cell counts 1554-P Earthquake stress 2849-PO 184-OR Differentiation 47-OR, 139-OR, 1760-P, 2197-P, behavior 147-OR, 152-OR, 1166-P Diabetes-related complications 482-P 2197-P Eating disorder 1338-P, 2502-PO Diabetes-related traits 1660-P Digenic 1808-P Eccentric endurance exercise 2475-PO, 2478-PO Diabetes-specific emotional distress 2514-PO Dilatation index 601-P Economic benefit 1248-P Diabetes-specific formula 777-P DIO rats 114-OR Ectonucleotidase 2222-P Diabetic autonomic neuropathy 54-OR Dipeptidyl peptidase-4 inhibitor 1088-P, 1090-P, Ectopic fat 2099-P, 2125-P Diabetic cardiomyopathy 488-P 1113-P, 1194-P, 1387-P, 1659-P, 1681-P, 1712-P, Edaravone 2366-PO Diabetic caregiver 1580-P 2078-P Education 309-OR, 683-P, 687-P, 693-P, 698-P, 701-P, Diabetic complications 606-P Direct costs 1235-P 708-P, 710-P, 712-P, 996-P, 1201-P, 2446-PO, Diabetic dyslipidemia 647-P, 653-P Direct sequencing 2804-PO 2449-PO, 2454-PO Diabetic embryopathy 18-OR, 1354-P Disease burden 1511-P Education and motivation 2531-PO Diabetic encephalopathy 1181-P Disease management 849-P Educational intervention 2458-PO Diabetic eye disease 623-P Disease progression 1033-P Educational outreach visit 1228-P Diabetic gastroparesis 2883-PO Disease severity 1216-P Educational preferences 2448-PO Diabetic glomerulosclerosis 109-OR Disparities 819-P, 850-P EEG 408-P Diabetic insulin sensitivity 1821-P Disposable pen device 2581-PO, 2585-PO Effectiveness 1273-P Diabetic ketoacidosis 280-OR, 2651-PO, 2682-PO, Disposition index 1847-P Efficacy 2639-PO 2740-PO Distress 2507-PO, 2723-PO Egfr 564-P, 2387-PO Diabetic kidney disease 104-OR, 535-P, 545-P, Distribution curves 1350-P E-health 1267-P 1523-P, 2725-PO Diverse populations 2-OR EHR 701-P Diabetic macular edema 160-OR, 611-P, 618-P, DKA 827-P Eif5a 1710-P 635-P DNA 63-OR, 540-P, 1636-P, 1762-P, 2260-P, 2279-P Elderly 262-OR, 804-P, 916-P, 933-P, 1211-P, 1213-P, Diabetic mellitus 1673-P Donepezil 1180-P 1236-P, 1257-P, 1278-P, 1283-P, 1497-P, 1497-P, Diabetic microvascular complications 2408-PO Dopamine 148-OR, 845-P, 2033-P 2585-PO, 2699-PO Diabetic model 2177-P Dose escalation 2551-PO Elective surgery 1477-P Diabetic mouse model 330-OR Dose-response 1054-P Electroacupuncture 2010-P Diabetic nephropathy 49-OR, 50-OR, 52-OR, Dosing frequency 210-OR, 1285-P Electrocardiogram 2325-PO 106-OR, 107-OR, 108-OR, 169-OR, 516-P, 518-P, Dpp-4 inhibitor 52-OR, 204-OR, 314-OR, 376-OR, Electron microscopic stereometry 517-P 521-P, 522-P, 522-P, 523-P, 526-P, 529-P, 531-P, 377-OR, 378-OR, 499-P, 506-P, 1061-P, 1071-P, Electronegative 660-P 534-P, 536-P, 539-P, 542-P, 543-P, 544-P, 546-P, 1080-P, 1097-P, 1106-P, 1133-P, 1134-P, 1135-P, Electronic alerts 1223-P 551-P, 554-P, 567-P, 568-P, 569-P, 572-P, 574-P, 1143-P, 1146-P, 1148-P, 1150-P, 1151-P, 1157-P, Electronic health data 1541-P, 1607-P 577-P, 578-P, 580-P, 581-P, 582-P, 584-P, 606-P, 1159-P, 1160-P, 1166-P, 1174-P, 1177-P, 1303-P, Electronic health record 265-OR, 823-P, 1252-P, 607-P, 671-P, 627-P, 629-P, 769-P, 1521-P, 1622-P, 1315-P, 1589-P, 1883-P, 1924-P, 2229-P, 2253-P, 1320-P, 2554-PO, 2668-PO, 2705-PO 1622-P, 2341-PO, 2367-PO, 2370-PO, 2376-PO, 2275-P, 2358-PO, 2614-PO, 2615-PO, 2620-PO, ELISA 2732-PO 2381-PO, 2385-PO, 2394-PO, 2397-PO, 2450-PO, 2621-PO, 2622-PO, 2629-PO, 2632-PO, 2636-PO, Embryonic stem (ES) cell 2966-PO 2736-PO 2801-PO, 2851-PO, 2905-PO Emergency department 672-P, 2319-PO, 2666-PO Diabetic peripheral neuropathy 51-OR, 588-P, 596-P, Draft ISO criteria 874-P Emergency room 958-P, 1070-P 602-P, 2396-PO DRG 1421-P Emerging adults 1220-P, 2797-PO Diabetic retinopathy 154-OR, 155-OR, 156-OR, Driving 6-OR, 822-P Emotional distress 844-P 157-OR, 158-OR, 161-OR, 453-P, 611-P, 615-P, Drug candidate 1178-P 237-OR, 460-P, 1082-P, 1085-P, 1092-P, 618-P, 620-P, 621-P, 622-P, 625-P, 626-P, 627-P, Drug compliance 698-P 1096-P, 1102-P, 1104-P, 1115-P, 1120-P, 1144-P, 629-P, 630-P, 631-P, 632-P, 634-P, 1506-P, 1522-P, Drug delivery systems 1250-P 2349-PO 2404-PO, 2410-PO, 2411-PO, 2659-PO Drug interactions 1165-P Empirical models 901-P Diabetic rhesus monkeys 528-P Drug screening 2208-P Empowerment 696-P Diabetic ulcer 671-P DSMP 1274-P Encapsulation 1742-P Diacerein 1057-P Dual bioelectrical impedance analysis 2128-P Encephalomyocarditis virus 1625-P Diacylglycerol 731-P, 1771-P Dual inhibition of SGLT1 and SGLT2 1083-P End stage renal disease 548-P, 562-P Diagnosis 179-OR, 1263-P, 1316-P, 1397-P, 1446-P, Dual receptor agonist 1001-P Endocrine disruptor 1555-P 1487-P Dual SGLT inhibitor 1131-P Endocrinology 1245-P, 2384-PO Diagnosis of diabetes 1471-P Dual therapy 1063-P Endogenous glucose production 146-OR, 1764-P, Diagnostic test 1444-P 66-OR, 69-OR, 71-OR, 1004-P, 1027-P, 1859-P, 1883-P Dialysis 374-OR, 2522-PO 1031-P, 1045-P Endogenous insulin 1318-P Dialysis initiation 2391-PO Duodenal-jejunal bypass sleeve 2144-P Endometrial cancer 1514-P Diapep277® 245-OR, 249-OR Durability 237-OR, 1061-P, 2587-PO, 2607-PO Endoplasmic reticulum stress 631-P, 1901-P, Diapin, 3 amino acid peptide 1158-P Duration 1323-P 2364-PO Diaport 968-P Dynamic bayesian network 991-P Endothelial adhesion 494-P

OR-Oral P-Poster PO-Published Only A759 Endothelial and cardiac cells 506-P Euglycemic clamp 113-OR, 917-P, 920-P Fatty acid potentiation of insulin secretion 2212-P Endothelial cell 624-P, 2206-P, 2336-PO Euthyroidism 2731-PO Fatty acid saturation 1914-P Endothelial dysfunction 272-OR, 447-P, 467-P, 468-P, Excess risk 1401-P Fatty acid sensing 2872-PO 500-P, 504-P, 505-P, 512-P Executive functioning 795-P, 802-P Fatty acid transporter 2858-PO Endothelial function 509-P, 601-P, 929-P, 1013-P, 66-OR, 67-OR, 553-P, 1006-P, 1013-P, Fatty acids 268-OR, 1792-P, 1921-P, 1944-P 1190-P, 2097-P 1017-P, 1018-P, 1023-P, 1025-P, 1026-P, 1034-P, Fatty 297-OR, 648-P, 664-P, 1000-P, 1429-P, Endothelial inflammation 2344-PO 1035-P, 1190-P, 1420-P, 1814-P, 1880-P, 1907-P, 1823-P, 1834-P, 1871-P, 1900-P, 1901-P, 2376-PO, Endothelial nitric oxide synthase 498-P 1965-P, 2118-P, 2601-PO 2421-PO, 2675-PO, 2859-PO Endothelial progenitor cell 501-P, 514-P, 2130-P, Exenatide and calcitonin 1049-P Fc gamma receptors 434-P SUBJECT INDEX 2143-P Exenatide LAR (bydureon) 2607-PO Feasibility 825-P Endothelium 92-OR, 445-P, 450-P, 497-P, 1310-P Exenatide once weekly 1182-P Feedback 716-P End-stage renal disease 552-P, 2379-PO, 2393-PO Exenatide treatment 1796-P Feeder-free culture 2966-PO Endurance exercise 741-P Exendin-4 1988-P, 2188-P, 2277-P, 2287-P, 2595-PO, Female adolescents 848-P Energy balance 1919-P 2914-PO 2428-PO Energy charge 1893-P Exercise 17-OR, 58-OR, 59-OR, 60-OR, 62-OR, Fermentation 747-P, 758-P Energy density 765-P 63-OR, 719-P, 721-P, 721-P, 722-P, 725-P, 727-P, Ferritin 457-P, 1486-P, 1829-P Energy expenditure 2139-P, 2456-PO 728-P, 729-P, 732-P, 734-P, 739-P, 743-P, 744-P, Fetal glucose genetics 75-OR Energy 2881-PO 745-P, 971-P, 1121-P, 1310-P, 1312-P, 2253-P, Fetal growth 1377-P Energy intake 1924-P 2337-PO, 2481-PO, 2483-PO, 2486-PO, 2487-PO, Fetal islet inflammation 48-OR Energy metabolism 769-P, 1702-P 2488-PO Fetal lipids 271-OR Enos 330-OR Exercise dose 737-P Fetal lung 271-OR ENPP1 activity 2257-P Exercise education 684-P, 2456-PO Fetal macrosomia 269-OR Enteral nutrition 167-OR Exercise Intensity 729-P, 737-P Fetal programming 273-OR, 1366-P, 1539-P, 2105-P Enteric neurons 2036-P, 2892-PO Exercise mimetics 64-OR Fetuin-A 503-P, 1884-P, 1904-P, 2382-PO Enteropathy 605-P Exercise prescription 2474-PO FFA1/GPR40 2276-P Enterovirus 350-OR, 1689-P, 2164-P, 2288-P Exercise testing 2479-PO FFAR1 1129-P Enzyme-based biosensor 2521-PO Exercise training 57-OR, 724-P, 726-P, 736-P FGF 473-P, EPC 2326-PO Exercise; MISR 718-P FGF19 2027-P Epiafzelechin 2977-PO Exercise-related 742-P FGF21 111-OR, 1019-P, 1894-P, 1912-P, 1991-P, Epicardial adipose tissue 489-P Exfoliated deciduous teeth conditioned medium 2006-P, 2009-P, 2011-P, 2321-PO, 2861-PO Epidemiological methods 1478-P 2234-P FGFR4 1900-P Epidemiological study 1406-P Exocrine pancreas 1025-P Fibrin 418-P, 1726-P Epidemiology 102-OR, 183-OR, 277-OR, 1282-P, Exocytosis 222-OR Fibrinogen 1417-P 1494-P, 1502-P, 1572-P, 1575-P, 1604-P, 2685-PO, Exome chip 322-OR Fibroblast cultures 496-P 2765-PO, 2769-PO, 2784-PO Exomes 325-OR Fibroblast 1367-P, 2294-P Epidemiology cancer 1476-P Exosomes 542-P Ficolin3 1482-P Epidemiology of diabetic complications 2736-PO Expenditures 1269-P Fingolimod 1725-P Epigenetic gene regulation 139-OR Experimental diabetes 1203-P First degree relatives 2331-PO, 2495-PO Epigenetics 126-OR, 1295-P, 1869-P, 2083-P Exploratory analysis 2646-PO First time CGM usage 843-P Epigenetics type 2 diabetes 1648-P Expression GWAS 127-OR First-ever ischemic stroke 1421-P Epigenome-wide association study 1648-P Expression levels 1822-P First-phase insulin response 352-OR Epigenomics 140-OR Expressive writing 8-OR Fitness 732-P Epinephrine 258-OR, 392-P Extracellular matrix 1870-P Fitness change 1552-P Epistasis 2131-P Extreme duration type 1 diabetes 1524-P, 1839-P FKBP5 1744-P Epo 613-P Eye screening services 2659-PO Flow cytometry 494-P, 2203-P Epsin deficiency 2065-P 653-P Flow-mediated dilation 467-P Eqtl 1637-P F0F1 atpase 666-P Fluid rention 1113-P Equation 570-P, 1215-P FAAM 117-OR, 667-P FOAD 2083-P ER 2243-P, 2280-P FADD 2181-P Follow-up study 83-OR, 1550-P ER stress 93-OR, 515-P, 1696-P, 1724-P, 1841-P, Family 785-P Food cues 214-OR 1907-P, 2176-P, 2294A-P Family density 790-P Food expenses 1277-P Eradication 1560-P Family history 1582-P Food intake 2023-P Erectile dysfunction 53-OR, 479-P, 585-P, 2733-PO, Family impact 809-P Foot 116-OR, 118-OR, 437-P, 632-P, 667-P, 669-P, 2737-PO Family members 309-OR, 806-P, 856-P, 2503-PO 672-P, 673-P, 675-P, 693-P, 702-P, 2326-PO, Erp57 2178-P Family physicians 2637-PO 2340-PO, 2433-PO, 2437-PO, 2439-PO, 2440-PO Erythrocyte deformability 619-P Family planning 792-P Foot ulcer 55-OR, 121-OR, 676-P, 677-P, 679-P, Erythrocytes 2016-P Family therapy 827-P 1267-P, 2822-PO 1819-P Fasting 756-P, 771-P, 1112-P, 1826-P, 2006-P Forkhead transcription factor Foxo1 1774-P E-selectin 2346-PO Fasting glucose 86-OR, 326-OR, 737-P, 2598-PO Formulation 938-P Esrage 2146-P Fasting insulin 1550-P Foxo 328-OR, 640-P Estimated GFR 447-P Fasting plasma glucose 1399-P, 1444-P Foxo1 45-OR, 141-OR, 438-P, 497-P, 2219-P, 2818-PO Estimated glomerular filtration rate 565-P, 567-P, Fasting plasma glucose target 388-P, 961-P FOXO3 2818-PO 1523-P, 2725-PO Fat 335-OR, 1767-P, 1924-P FPG variability 2551-PO Estradiol 2077-P Fat distribution 2492-PO Free fatty acids 219-OR, 657-P, 731-P, 1463-P, Estrogen 110-OR, 726-P, 2189-P Fat intake 1533-P 1807-P, 1874-P, 1932-P, 2064-P, 2104-P, 2235-P Estrogen signaling 2289-P Fat loss model 2081-P Free mydriatic fundus photography 2410-PO Ethiopians 1559-P Fat mass 1113-P Frequency 886-P Ethnic diabetes genetic 306-OR Fat oxidation and lipolysis 2073-P FRET imaging 2211-P Ethnic differences 1362-P Fatty acid 1786-P Friend support 847-P Ethnicity 55-OR, 686-P, 1374-P, 1496-P, 1570-P, Fatty acid metabolism 51-OR Fructose 40-OR, 1901-P, 2071-P 1588-P, 1591-P, 2157-P Fatty acid oxidation 1776-P Fruit and vegetable intake 755-P

A760 OR-Oral P-Poster PO-Published Only FTO gene 2817-PO Gestational diabetes 73-OR, 74-OR, 75-OR, 151-OR, Glucoregulatory 186-OR, 1753-P, 1990-P, 2014-P Fuel detoxification 2239-P 267-OR, 270-OR, 272-OR, 816-P, 1357-P, 1358-P, Glucose 881-P, 1009-P, 1313-P, 1498-P, 2330-PO, Fulminant type 1 diabetes 1697-P, 2798-PO 1359-P, 1361-P, 1362-P, 1363-P, 1365-P, 1367-P, 2875-PO Fumarate 1748-P 1373-P, 1374-P, 1375-P, 1380-P, 1383-P, 1387-P, Glucose absorption 1458-P Functional genomics 1624-P, 1716-P 1390-P, 1368-P, 1369-P, 1372-P, 1376-P, 1377-P, Glucose and insulin metabolism 1826-P Functional magnetic resonance imaging 2106-P 1379-P, 1381-P, 1385-P, 1386-P, 1389-P, 1392-P, Glucose and lipid metabolism 1876-P Functional maturation 47-OR 1393-P, 1394-P, 1442-P, 1445-P, 1454-P, 1579-P, Glucose anomers 2534-PO G protein coupled receptor 521-P 1583-P, 1594-P, 1654-P, 2686-PO, 2689-PO, Glucose based peritoneal dialysis solution 887-P G0S2 2859-PO 2691-PO, 2692-PO Glucose control 756-P, 1138-P, 1835-P, 2218-P, GABA 231-OR, 744-P, 2266-P Gestational fasting plasma glucose 2690-PO 2602-PO SUBJECT INDEX GAD65 auto antibodies 1688-P Gestational obesity 1385-P Glucose counterregulation 20-OR, 130-OR GADA 1464-P, 2407-PO Gestational weight gain 74-OR, 76-OR, 1365-P, Glucose dependent insulinotropic polypeptide Gadd45a 1947-P 1365-P, 1383-P, 1388-P 2024-P, 2028-P Gait 121-OR Ghrelin 1983-P, 2012-P, 2050-P, 2292-P, 2871-PO, Glucose exposure 890-P Galectin-3 1448-P 2880-PO, 2890-PO Glucose fluctuation 592-P, 1353-P, 2433-PO, Gallbladder 2894-PO GIGD 2020-P 2643-PO GALNT2 1822-P GK rat 44-OR Glucose homeostasis 17-OR, 62-OR, 1453-P, 1654-P, Gap junction 2214-P Glargine 940-P, 944-P, 988-P, 1242-P, 1574-P, 1664-P, 2200-P, 2898-PO, 2902-PO Gas chromatography 543-P 2302-PO, 2573-PO Glucose infusion rate 113-OR, 920-P Gas6 625-P Glargine U300 113-OR, 920-P Glucose intervention 958-P Gastric bypass 153-OR, 554-P, 587-P, 1825-P, 2012-P, Glia 1788-P Glucose intolerance 1372-P, 2702-PO 2049-P, 2116-P, 2154-P, 2158-P 1111-P, 2811-PO Glucose level movement trends 2543-PO Gastric emptying 591-P, 1032-P, 1830-P, 1847-P, 1165-P Glucose management program 261-OR 2007-P, 2118-P, 2592-PO XL 1059-P Glucose metabolism 150-OR, 188-OR, 661-P, 750-P, Gastric inhibitory peptide 2024-P Globular adiponectin 1936-P 925-P, 1717-P, 1827-P, 1992-P, 2211-P, 2853-PO, Gastric inhibitory polypeptide 2091-P Glomerular filtration rate 169-OR, 417-P, 563-P, 2912-PO Gastric stimulation 919-P 570-P Glucose meter 867-P Gastroc recession 671-P Glomerular mesangial cells 527-P Glucose monitoring 12-OR, 176-OR, 862-P, 2533-PO Gastrointestinal adverse events 425-P GLP-1 52-OR, 68-OR, 70-OR, 110-OR, 115-OR, Glucose phosphorylation 1934-P Gastrointestinal endoscopy 605-P 188-OR, 191-OR, 198-OR, 366-OR, 445-P, 490-P, Glucose prediction 991-P Gastrointestinal events 2649-PO 564-P, 1003-P, 1012-P, 1016-P, 1041-P, 1080-P, Glucose production 218-OR, 1999-P Gastrointestinal hormones 2017-P 1087-P, 1089-P, 1109-P, 1169-P, 1181-P, 1183-P, Glucose sensor 865-P, 2048-P, 2530-PO Gastrointestinal motility 189-OR 1589-P, 1823-P, 1872-P, 1892-P, 1895-P, 1935-P, Glucose stimulated insulin secretion 2212-P, 2227-P, Gastroparesis 591-P 1987-P, 1989-P, 1991-P, 2023-P, 2034-P, 2111-P, 2265-P GC7 1710-P 2148-P, 2231-P, 2257-P, 2589-PO, 2598-PO, Glucose tolerance 729-P, 1167-P, 1381-P, 1642-P, GCK MODY 1995-P, 2025-P, 2805-PO 2606-PO, 2654-PO, 2889-PO, 2906-PO 1747-P, 1983-P, 2020-P, 2129-P, 2923-PO GCKR 1287-P GLP-1 analogs 137-OR, 1026-P, 1040-P, 2186-P Glucose transport 221-OR, 223-OR, 1187-P, 1794-P, GDM 1384-P, 1456-P, 2020-P GLP-1 receptor agonist 301-OR, 916-P, 950-P, 1814-P, 1934-P, 1940-P, 2322-PO Gender 452-P, 458-P, 464-P, 765-P, 1421-P, 2511-PO, 1000-P, 1002-P, 1008-P, 1013-P, 1024-P, 1027-P, Glucose, BP, lipid control 207-OR 2751-PO, 2779-PO 1029-P, 1031-P, 1033-P, 1037-P, 1038-P, 1047-P, Glucose, macrosomia 1391-P Gene 1641-P, 1675-P 1048-P, 1420-P, 1824-P, 2174-P, 2184-P, 2594-PO, Glucotoxicity 1748-P, 2223-P, 2247-P, 2248-P Gene chemical interactions 2807-PO 2596-PO, 2602-PO Glucotrack 893-P Gene diet interaction 2756-PO GLP-1 therapies and Glulisine 2574-PO 525-P, 1645-P, 1947-P, 2011-P, 2599-PO GLUT12 1981-P 2201-P Glucagon 14-OR, 112-OR, 149-OR, 402-P, 404-P, Glut2 transporter 2177-P Gene level test 320-OR 922-P, 1003-P, 1014-P, 1015-P, 1053-P, 1072-P, Glut4 87-OR, 220-OR, 222-OR, 1791-P Gene polymorphism 1661-P, 1668-P, 1674-P, 1708-P 1086-P, 1088-P, 1643-P, 1991-P, 1995-P, 1999-P, Glutamate 1997-P Gene regulation 1751-P 2000-P, 2002-P, 2023-P, 2029-P, 2034-P, 2119-P, Glutamate dehydrogenase 2079-P Genetic architecture of type 2 diabetes 320-OR 2379-PO, 2601-PO Glutamic acid decarboxylase 1107-P Genetic association 122-OR, 321-OR, 1649-P, Glucagon antagonist 1043-P Glutathione S- 2799-PO 1660-P, 1665-P Glucagon dynamics 2022-P Gly385Arg polymorphism 1900-P Genetic epidemiology 1629-P Glucagon kinetics 2021-P Glycaemic control 1505-P, 1608-P, 2599-PO Genetic influence 2136-P Glucagon like peptide 298-OR Glycaemic targets 711-P Genetic mapping 1642-P Glucagon loading test 2238-P Glycated hemoglobin 567-P, 1455-P, 2527-PO, Genetic polymorphism 607-P, 2799-PO 1999-P 2532-PO, 2774-PO Genetic research 1646-P Glucagon receptor antagonist 1118-P Glycation mechanism 2534-PO Genetic risk prediction 1655-P Glucagon secretion 1841-P, 2001-P, 2286-P Glycemia 1063-P, 2007-P, 2121-P, 2202-P, 2318-PO, Genetic testing 778-P, 779-P Glucagon stimulation test 1490-P 2745-PO Genetics 123-OR, 126-OR, 323-OR, 346-OR, 348-OR, Glucagon-like peptide-1 455-P, 556-P, 600-P, 642-P, Glycemic control 164-OR, 165-OR, 277-OR, 318-OR, 644-P, 1543-P, 1582-P, 1626-P, 1638-P, 1644-P, 646-P, 1014-P, 1018-P, 1020-P, 1021-P, 1032-P, 380-OR, 398-P, 407-P, 598-P, 728-P, 764-P, 766-P, 1647-P, 1651-P, 1666-P, 1671-P, 1691-P 1731-P, 1986-P, 1986-P, 2188-P, 2360-PO 783-P, 840-P, 960-P, 988-P, 995-P, 999-P, 1017-P, Genital mycotic infection 1069-P Glucaokinase activator 1108-P 1074-P, 1091-P, 1123-P, 1222-P, 1223-P, 1223-P, Genital tract infection 1083-P Glucocorticoid 946-P, 1744-P, 1744-P 1227-P, 1245-P, 1282-P, 1350-P, 1577-P, 1581-P, GENNID study pedigree 322-OR Glucocorticoid induced hyperglycemia 2704-PO 1782-P, 2414-PO, 2497-PO, 2530-PO, 2538-PO, Genome sequencing 1633-P Glucocorticoid receptor II antagonists 1850-P 2559-PO, 2560-PO, 2589-PO, 2603-PO, 2607-PO, Genome-wide association study 327-OR, 635-P, Glucocorticoids 1850-P 2625-PO, 2658-PO, 2751-PO, 2765-PO, 2774-PO, 1632-P, 1640-P, 1654-P, 1656-P, 1658-P 371-OR, 389-P, 1121-P, 2635-PO, 2852-PO 2780-PO, 2881-PO, 2945-PO Genus crotalaria 2420-PO Glucokinase activator 925-P, 1051-P, 1051-P, 2635-PO Glycemic deterioration 1666-P Geographical variation 1590-P Glucolipotoxicity 2241-P Glycemic index 1539-P Geriatrics 858-P 218-OR, 330-OR, 1864-P, 1872-P, Glycemic management 2700-PO Gerodiab 2308-PO 1892-P, 1910-P Glycemic targets 1214-P

OR-Oral P-Poster PO-Published Only A761 Glycemic traits 1633-P, 2808-PO Health risk behaviors 1314-P Histone methylation 106-OR Glycemic variability 132-OR, 175-OR, 399-P, 427-P, Health satisfaction 1220-P Histone modification 139-OR 863-P, 875-P, 882-P, 884-P, 959-P, 2523-PO, Health screening 1479-P HLA 128-OR, 1530-P 2553-PO, 2626-PO Health services use 264-OR HMGB1 654-P Glycogen 1773-P, 2002-P, 2836-PO Health system barriers 1240-P Hmgcoa reductase inhibitor 661-P, 1864-P Glycogen derived lactate 1919-P Healthcare costs 482-P, 670-P, 670-P, 1281-P HNF1A-MODY 1627-P, 1995-P, 2025-P, 2261-P, 94-OR, 616-P, 1926-P, 2534-PO Healthcare providers 854-P 2529-PO, 2805-PO Glycosylated haemoglobin 1336-P Health-related quality of life 1493-P, 2949-PO HNF1B 1670-P Glycosylation 492-P, 513-P Healthy lifestyle 1308-P HO-1 1894-P, 2910-PO SUBJECT INDEX Glyoxalase 1937-P Healthy subjects 733-P Holiday weight gain 2493-PO Goal hemoglobin A1C 1065-P Hearing loss 2401-PO HOMA-B 1023-P, 1436-P, 1611-P, 1846-P, 2719-PO GOAT 2880-PO Heart 25-OR, 26-OR, 93-OR, 292-OR, 473-P, 1810-P, Homeostasis 771-P Golgi 332-OR 1926-P, 1973-P Homocysteine 1062-P Goto-kakizaki rat 1833-P Heart failure 559-P, 1422-P, 1435-P, 1470-P, 2120-P, secretion 2191-P Gout 1558-P 2928-PO Hospital 316-OR, 318-OR, 1483-P GPBAR1 2041-P Heart rate variability 54-OR, 583-P, 2309-PO, Hospital costs 260-OR GPER 2255-P 2395-PO, 2402-PO Hospital mortality 167-OR GPR119 agonist 2045-P, 2654-PO Heat shock protein 724-P, 1772-P, 1837-P, 2246-P Hospital patients 2549-PO GPR40 1129-P Height 2015-P Hospital readmission 262-OR, 311-OR, 1217-P G-protein coupled receptors 2976-PO Helicobacter pylori 1560-P, 1577-P Hospitalization 995-P, 2306-PO, 2695-PO Graves’disease 1492-P Helminth infection 2084-P Hostility 818-P Gray matter atrophy 1520-P Hematopoietic cells and insulin action 1781-P HPLC-ESI-MS/MS 1809-P, 1818-P GRB10 1638-P Heme oxygenase-1 430-P Hscrp 444-P, 2323-PO, 2346-PO, 2352-PO Group education 304-OR Heme transfer 513-P Hsp90 138-OR Group lifestyle balance 682-P, 1277-P Hemodialysis 562-P, 2527-PO Htpoglycemia 2555-PO Group size 1221-P Hemoglobin a1c 1350-P, 1369-P, 1469-P, 1598-P, Human adipocytes 2011-P, 2156-P Group visits 1271-P 2714-PO, 2749-PO Human brown adipose tissue 2008-P, 2140-P Growth 1590-P Hemostatic and cerebral abnormalities 135-OR Human brown fat 97-OR 1848-P Hepatic and endothelial lipogenesis 1798-P Human CD4 T cells 283-OR GRP78 1724-P Hepatic ER stress 1905-P Human factors 2586-PO GSIS 367-OR, 2228-P, 2263-P Hepatic fat content 163-OR Human gallbladder 2198-P GSK2330672 1170-P Hepatic glucose production 149-OR, 912-P, 913-P, Human islet composition 2203-P GST 251-OR 1874-P, 1893-P Human islet derived precursor cells 2164-P Gtpase 332-OR Hepatic glycemic control 1121-P Human islets 378-OR, 1728-P Guided clinical decision-making 890-P Hepatic glycogen 722-P Human muscle biopsy 2888-PO Gut and pancreas hormone 192-OR Hepatic inflammation 1789-P Human obesity 2108-P Gut hormone 2028-P, 2148-P Hepatic insulin resistance 1870-P, 1879-P Human pancreatic islets 126-OR, 2254-P Gut microbiota 192-OR, 295-OR, 1925-P, 2145-P Hepatic insulin sensitivity 730-P, 1821-P, 1928-P Human progenitor cells 2288-P GWAS 644-P, 1635-P, 1669-P, 1676-P, 2808-PO Hepatic lipid metabolism 1774-P Human skeletal muscle 1800-P, 1806-P, 1961-P H2O2 emission 1968-P Hepatic mitochondrial function 1879-P Human umbilical vein endothelial cells Haem oxygenase-1 2762-PO Hepatic signaling 38-OR 2360-PO Haemodialysis 896-P Hepatic steatosis 642-P, 2042-P Hyaloid retinal vessels 620-P Hair follicles 1727-P Hepatic vs. peripheral 1863-P Hyaluronan degradation 510-P Handle region peptide 2969-PO Hepatitis 2861-PO Hyaluronic acid catabolism 510-P Haptoglobin 513-P, 1199-P Hepatitis C virus 2829-PO Hyaluronidase 969-P Haptoglobin genotype 502-P, 1398-P, 1416-P, Hepatocellular carcinoma 1476-P, 2067-P Hydrogen sulfide 2365-PO 2732-PO Hepatocyte 1786-P Hyperbaric oxygen therapy 1705-P Hazard ratio 1469-P Hepatocyte growth factor 269-OR Hypercaloric diet 148-OR, 1877-P, 1928-P Hba1c 278-OR, 345-OR, 398-P, 452-P, 458-P, 688-P, Hepato-preferential 912-P, 913-P Hypercholesterolemia 652-P 768-P, 857-P, 1257-P, 1444-P, 1456-P, 1470-P, Hepatoselective glucokinase activator 2635-PO Hyperglycemia 9-OR, 146-OR, 152-OR, 167-OR, 1471-P, 1489-P, 1495-P, 1504-P, 1595-P, 1599-P, Hepatoselectivity 1903-P 174-OR, 463-P, 595-P, 647-P, 871-P, 932-P, 942-P, 1601-P, 1612-P, 2100-P, 2538-PO, 2540-PO, Hepatosteatosis 1881-P, 1906-P 958-P, 1076-P, 1081-P, 1275-P, 1763-P, 1783-P, 2620-PO, 2628-PO, 2713-PO, 2727-PO Hepg2 cells 2595-PO 1822-P, 1853-P, 1855-P, 2549-PO HDAC inhibitors 302-OR Herbal formula 1202-P Hyperglycemia and cost of healthcare 2660-PO HDL 343-OR, 666-P 2648-PO Hyperglycemic clamp 2846-PO, 2890-PO HDL cholesterol 414-P, 677-P, 1209-P, 1416-P, Heritability 168-OR Hyperglycemic emergency 274-OR 1565-P Heterogeneity 705-P, 2683-PO Hyperinsulinemia 1288-P, 1811-P, 2068-P HDL composition 424-P Hiapp 2167-P Hyperinsulinemic euglycemic clamp 32-OR, 84-OR, HDL function 2415-PO HIF-1α 109-OR 1800-P, 1800-P Head-to-head 1116-P High Density Lipoprotein 514-P, 1300-P, 1789-P Hyperlipidemia 243-OR, 637-P, 1853-P, 2093-P, Healing 676-P, 2432-PO High fat diet 46-OR, 1197-P, 1773-P, 1816-P, 1878-P, 2420-PO, 2421-PO Health and delivery 1279-P 1898-P, 1915-P, 1996-P, 2030-P, 2069-P Hyperphagia 2879-PO Health and retirement study 1395-P High glucose 2365-PO, 2366-PO Hypertension 435-P, 866-P, 1409-P, 1436-P, 2328-PO, Health behavior 782-P High HDL 650-P 2746-PO Health care delivery 211-OR, 1219-P, 1267-P High protein diet 776-P, 1972-P, 2155-P Hyperthyroidism 1687-P Health care provider education 696-P, 1228-P High-content screening 2180-P Hypertrophy 473-P Health care transition 1249-P High-throughput screening 1100-P, 1168-P Hyperuricemia 2779-PO Health disparities 684-P, 1646-P, 2659-PO 87-OR, 395-P, 838-P Hypoandrogenic 2226-P Health economics 1226-P, 1230-P Hips 2887-PO Hypocaloric diet 1534-P, 2491-PO Health examination 694-P Hispanic 752-P, 1404-P, 1652-P Hypoclycemia hospital 342-OR Health related quality of life 2944-PO Histological heterogeneity 551-P Hypoglycaemia 397-P, 1112-P, 2316-PO

A762 OR-Oral P-Poster PO-Published Only Hypoglycemia 132-OR, 133-OR, 170-OR, 208-OR, Impaired glycemia 2103-P, 2133-P Inos 1891-P 229-OR, 230-OR, 231-OR, 232-OR, 233-OR, Implementing DPP with type II diabetics 689-P Inpatient 315-OR, 1263-P, 1446-P 234-OR, 235-OR, 252-OR, 255-OR, 258-OR, Improvement 2318-PO, 2460-PO Inpatient complications 317-OR, 878-P 259-OR, 274-OR, 275-OR, 279-OR, 365-OR, Improving hba1c 552-P Inpatient diabetes 2766-PO 389-P, 389-P, 390-P, 390-P, 392-P, 393-P, 395-P, Imputation 1632-P Inpatient diabetes diet 2882-PO 398-P, 399-P, 399-P, 400-P, 401-P, 402-P, 403-P, IMT 2343-PO Inpatient diabetes management 964-P, 2882-PO 404-P, 405-P, 406-P, 407-P, 408-P, 409-P, 410-P, In vivo corneal confocal microscopy 575-P Inpatient glycemic control 699-P, 878-P, 898-P 411-P, 412-P, 413-P, 477-P, 549-P, 722-P, 725-P, In vivo hepatic metabolism 1911-P Inpatient hyperglycemia 317-OR, 260-OR, 314-OR, 864-P, 882-P, 897-P, 935-P, 942-P, 955-P, 971-P, In vivo metformin treatment 1780-P 878-P 984-P, 1070-P, 1151-P, 1214-P, 1256-P, 1259-P, Incidence 83-OR, 212-OR, 1319-P, 1357-P, 1415-P, Inpatients 2562-PO SUBJECT INDEX 1268-P, 1319-P, 1483-P, 1493-P, 1593-P, 1733-P, 1527-P, 1549-P, 1550-P, 1557-P, 1615-P, 1619-P, INS-1 2265-P 1741-P, 1840-P, 1891-P, 1989-P, 2297-PO, 2306-PO, 2771-PO, 2786-PO Insertion site 176-OR 2298-PO, 2299-PO, 2300-PO, 2301-PO, 2308-PO, Incidence of MI and stroke 1408-P INS-IGF2 286-OR 2309-PO, 2310-PO, 2311-PO, 2319-PO, 2525-PO, Incident diabetes 1395-P, 1544-P, 2122-P Insulin sensitivity 2127-P 2546-PO, 2556-PO, 2632-PO, 2758-PO Incident disability 1395-P Insulin 88-OR, 191-OR, 281-OR, 328-OR, 365-OR, Hypoglycemia alarm 2303-PO Incident type 2 diabetes 182-OR 385-OR, 697-P, 821-P, 938-P, 946-P, 956-P, 957-P, Hypoglycemia rates 961-P Income 1335-P 1036-P, 1136-P, 1179-P, 1205-P, 1206-P, 1280-P, Hypoglycemia syndrome 153-OR Increasing diabetes 2657-PO 1317-P, 1387-P, 1809-P, 1818-P, 1902-P, 1903-P, Hypoglycemic agents 1423-P Incretin 197-OR, 1009-P, 1303-P, 1315-P, 1998-P, 2016-P, 2053-P, 2198-P, 2216-P, 2216-P, 2393-PO, Hypoglycemic range 172-OR 2018-P, 2024-P, 2028-P, 2036-P, 2195-P 2446-PO, 2558-PO, 2572-PO, 2597-PO, 2601-PO, Hypogonadism 1994-P, 2733-PO Incretin effect 1830-P 2737-PO, 2834-PO, 2852-PO, 2867-PO, 2889-PO, Hypothalamic glucose sensing 253-OR, 254-OR Incretin hormones 189-OR, 1992-P, 2025-P, 2046-P, 2890-PO Hypothalamic inflammation 1918-P 2379-PO, 2891-PO Insulin action 223-OR, 323-OR, 331-OR, 1081-P, Hypothalamus 252-OR, 2047-P, 2051-P, 2054-P, Incretin response 2892-PO 1769-P, 1933-P, 1952-P 2872-PO Incretin therapy in T1D 1026-P Insulin administration 319-OR, 965-P Hypothermia 463-P Incretins 1016-P, 1148-P, 1659-P, 1828-P, 2090-P, Insulin analogs 939-P, 960-P, 963-P, 1595-P, Hypoxia 94-OR, 1735-P, 1736-P, 2055-P, 2060-P, 2123-P, 2624-PO, 2868-PO, 2873-PO, 2297-PO, 2560-PO, 2567-PO, 2575-PO, 2189-P 2913-PO 2751-PO Hypoxia inducibel factor 225-OR, 1851-P Incretins, GIP, GLP 1001-P, 1011-P Insulin and IGF-1 receptors 143-OR Hypoxia, obesity, insulin resistance 1802-P 2763-PO Insulin aspart 256-OR, 2560-PO Hypoxia-inducible factor 1-alpha 294-OR Indian children 1311-P Insulin auto antibodies 286-OR IA-2 non-synonymous snps 1620-P Indigenous 2760-PO Insulin bolus delivery 966-P Iabetes mellitus 1585-P Indirect costs 1235-P Insulin clamp 2853-PO IADPSG criteria 1374-P, 1442-P Induced pluripotent stem cells 1623-P, 2196-P, Insulin clearance 1649-P, 1861-P IAPP 340-OR 2208-P, 2838-PO Insulin deficient diabetes 1695-P, 1702-P Iatrogenic hyperglycemia 2767-PO Induction of diabetes 2258-P 65-OR, 388-P, 405-P, 742-P, 911-P, Idegasp 909-P, 926-P, 945-P, 947-P INDY 1868-P 914-P, 933-P, 934-P, 935-P Identification 859-P Infant weight gain 213-OR, 1368-P Insulin degradation 91-OR Identity 847-P Infarction 2324-PO Insulin degrading enzyme 1811-P IFG 1848-P, 2027-P, 2488-PO, 2839-PO Infection 2438-PO Insulin degrading enzyme 1168-P, 2228-P IGT 1073-P Infection syndrome 1518-P Insulin delivery 985-P, 2580-PO IKK 1820-P Inflammasome 337-OR, 1765-P Insulin delivery device 990-P IL-1 beta 1678-P, 2162-P Inflammation 95-OR, 168-OR, 204-OR, 247-OR, Insulin delivery route 2853-PO IL-1RA 1006-P 250-OR, 266-OR, 268-OR, 290-OR, 295-OR, Insulin dependent diabetes mellitus 2154-P IL-2 2340-PO 335-OR, 415-P, 464-P, 615-P, 799-P, 1006-P, 2550-PO, 2570-PO, 2610-PO IL-27 1631-P 1020-P, 1304-P, 1525-P, 1624-P, 1680-P, 1682-P, Insulin diurnal pattern 1821-P IL-6 polymorphism 254-OR, 2825-PO 1712-P, 1716-P, 1717-P, 1719-P, 1747-P, 1750-P, Insulin dose 316-OR, 965-P, 1230-P, 2577-PO, Illness beliefs 2515-PO 1752-P, 1783-P, 1819-P, 1932-P, 1971-P, 2061-P, 2794-PO, 2946-PO Imaging 366-OR 2107-P, 2107-P, 2135-P, 2155-P, 2159-P, 2173-P, Insulin gene 2161-P, 2247-P, 2260-P IMCL 1929-P 2179-P, 2364-PO, 2878-PO, 2919-PO, 2938-PO, 67-OR, 742-P, 914-P, 937-P, 948-P, Immediate post-op complications 454-P 2943-PO 951-P, 955-P, 962-P, 1017-P, 1034-P, 1813-P, Immigrants 1559-P, 2689-PO Inflammatory bowel disease 2891-PO 2550-PO, 2559-PO, 2570-PO, 2833-PO, 2841-PO, Immortalization 97-OR Inflammatory factor 631-P 2842-PO Immune 1304-P Inflammatory markers 462-P, 1605-P, 1605-P Insulin glargine metabolites 944-P Immune modulation 1022-P, 1207-P Informal care 1580-P 927-P Immune privilege 1727-P Informatics 403-P Insulin granule 2246-P Immune tolerance 1720-P, 2634-PO, 2642-PO Infrared 602-P Insulin granule exocytosis 369-OR, 2220-P Immunogenetics 1621-P INGAP-PP 2250-P Insulin induced 2588-PO Immunoglobulin 1706-P Inhaled insulin 982-P Insulin induced recruitment 1951-P Immunohistochemistry 2846-PO Inhibitors 338-OR Insulin induced vasoreactivity 34-OR, 1960-P Immunoisolation 1742-P Inhospital complications 959-P Insulin infusion 970-P Immunology 1680-P, 1698-P In-hospital diabetes care 1198-P Insulin initiation 1213-P, 1236-P, 1237-P, 1238-P, Immunometabolism 1695-P, 1706-P Inhospital hyperglycemia 959-P 1262-P Immunomodulation 1723-P Initial diabetes therapy 1059-P Insulin injection 979-P, 997-P Immunoregulation 2287-P Initial insulin 2552-PO Insulin intensification 256-OR Immunotherapy 244-OR, 1698-P, 1709-P Initial yreatment 2437-PO Insulin omission 1338-P Impaired fasting glucose 751-P, 1413-P, 1588-P, Injection force 1046-P Insulin order sets 1273-P 2323-PO, 2344-PO Injury 2319-PO Insulin pen 804-P, 1046-P Impaired glucose metabolism 2513-PO Inkt-cell 1711-P Insulin pharmacodynamics 989-P, 2843-PO Impaired glucose tolerance 1089-P, 1413-P, 1458-P, Innate Inflammation 1683-P Insulin potency 2843-PO 1832-P, 1913-P, 2030-P Innervation 2080-P Insulin producing cells 2196-P

OR-Oral P-Poster PO-Published Only A763 Insulin pump 11-OR, 357-OR, 936-P, 966-P,974-P, Intensive insulin therapy 312-OR, 921-P, 928-P, Islet graft 137-OR, 361-OR 986-P, 994-P, 995-P, 1341-P, 2449-PO, 2531-PO, 954-P, 987-P, 1613-P Islet imaging 198-OR, 2163-P 2579-PO, 2584-PO, 2587-PO Interactions 1661-P Islet inflammation 2283-P 1759-P, 2817-PO Interactive exercise game 740-P Islet morphology 2240-P Insulin receptor knockout 22-OR, 90-OR Interference 1489-P Islet oscillations 2211-P Insulin receptor substrate 1 21-OR, 201-OR, 1512-P signaling 1625-P Islet transplantation 20-OR, 130-OR, 131-OR, Insulin receptor trafficking 227-OR Interferon tau 2653-PO 132-OR, 133-OR, 134-OR, 135-OR, 137-OR, Insulin regimen 390-P 1β inhibitor 444-P 359-OR, 360-OR, 363-OR, 1727-P, 1729-P, 1733-P, Insulin requirement 972-P, 2158-P Interleukin-1 1057-P 1735-P, 1741-P, 2193-P SUBJECT INDEX Insulin resistance 21-OR, 26-OR, 29-OR, 32-OR, Interleukin-4 2113-P Islet vascularity 48-OR 33-OR, 58-OR, 78-OR, 80-OR, 93-OR, 140-OR, Interleukin-6 gene 2820-PO Islet vasculature 1854-P 141-OR, 150-OR, 200-OR, 201-OR, 219-OR, Interleukin-9 1621-P Islets 42-OR, 364-OR, 943-P, 1597-P, 1729-P, 2192-P, 223-OR, 227-OR ,291-OR, 293-OR, 294-OR, Intermittent hypoxia 1851-P 2210-P, 2222-P 329-OR, 381-OR, 431-P, 546-P, 641-P, 662-P, Intermittent high glucose 645-P Isoprostanes 166-OR 736-P, 759-P, 774-P, 918-P, 954-P, 1114-P, 1180-P, International 211-OR Isotope tracer 1955-P 1185-P, 1296-P, 1309-P, 1366-P, 1412-P, 1436-P, Internet blood glucose monitoring 868-P, 903-P ISR 2621-PO 1462-P, 1463-P, 1480-P, 1485-P, 1498-P, 1498-P, Internet intervention 6-OR, 746-P, 746-P, 822-P Israel 1559-P 1533-P, 1534-P, 1554-P, 1556-P, 1578-P, 1585-P, Internet-based education 681-P IST 2329-PO 1617-P, 1642-P, 1674-P, 1717-P, 1743-P, 1743-P, Interneuron 88-OR Japanese 559-P, 763-P, 1048-P, 1163-P, 2145-P, 1753-P, 1770-P, 1777-P, 1778-P, 1779-P, 1786-P, Inter-organ metabolic crosstalk 1781-P 2963-PO 1789-P, 1792-P, 1793-P, 1797-P, 1804-P, 1805-P, Interstitial 1976-P Japanese patients with T2DM 1144-P 1808-P, 1816-P, 1819-P, 1837-P, 1844-P, 1845-P, Interstitial glucose, hypoglycemia 860-P Jin lida granule 1913-P 1849-P, 1860-P, 1860-P, 1863-P, 1863-P, 1875-P, Intervention 245-OR, 249-OR, 788-P, 855-P JNK 1960-P, 2365-PO 1878-P, 1886-P, 1894-P, 1895-P, 1904-P, 1920-P, Intervention cost 207-OR Joint commission 411-P 1929-P, 1932-P, 1935-P, 1936-P, 1943-P, 1953-P, Intestinal 1998-P Joint mobility 675-P 1957-P, 1962-P, 1964-P, 1966-P, 1970-P, 1971-P, Intestinal apob48 643-P KATP channel 146-OR, 353-OR, 1844-P, 1859-P, 1979-P, 1980-P, 1981-P, 2015-P, 2049-P, 2058-P, Intestine 22-OR, 90-OR 2190-P 2060-P, 2064-P, 2092-P, 2106-P, 2106-P, 2107-P, Intracavernosal pressure 585-P KCNJ11 2190-P, 2821-PO 2120-P, 2125-P, 2132-P, 2191-P, 2219-P, 2225-P, Intracoronary ultrasound 2728-PO KCNQ1 1636-P 2240-P, 2362-PO, 2672-PO, 2719-PO, 2735-PO, Intradermal 975-P 774-P 2793-PO, 2817-PO, 2857-PO, 2859-PO, 2860-PO, Intramusclar fat 1143-P Ketohexokinase 2071-P 2874-PO, 2898-PO, 2899-PO, 2901-PO, 2915-PO, Intramyocellular diacylglycerol 1953-P 2847-PO 2938-PO, 2969-PO Intranasal 978-P Ketosis prone diabetes 1688-P Insulin secretion 190-OR, 194-OR, 331-OR, 334-OR, Intrapartum 2687-PO Kidney 91-OR, 532-P, 556-P 368-OR, 1457-P, 1659-P, 1699-P, 1728-P, 1830-P, Intraperitoneal 16-OR Kidney cancer 540-P 1831-P, 1834-P, 1841-P, 1843-P, 1847-P, 1853-P, Intraperitoneal insulin therapy 968-P Kidney disease progression 573-P 1856-P, 1909-P, 1920-P, 1963-P, 1983-P, 2000-P, Intra-uterine growth retardation 1923-P Kidney dysfunction 1674-P 2129-P, 2182-P, 2194-P, 2220-P, 2222-P, 2237-P, Intrauterine selection 1398-P Kidney failure 180-OR, 541-P, 1503-P, 1513-P 2238-P, 2241-P, 2242-P, 2246-P, 2250-P, 2256-P, Invariant natural killer T cell 1750-P Kidney function 561-P 2257-P, 2269-P, 2273-P, 2274-P, 2290-P, 2598-PO In-vitro fertilization 1996-P Kidney transplant 1731-P, 1732-P, 1738-P Insulin sensitivity 35-OR, 59-OR, 84-OR, 134-OR, IPLA2 339-OR, 2812-PO Kimchi 747-P, 758-P 216-OR, 354-OR, 501-P, 509-P, 720-P, 733-P, Ips 1793-P Kinetics 2140-P 735-P, 921-P, 951-P, 981-P, 1096-P, 1292-P, IRAK-1 1747-P Kinins receptors 508-P 1302-P, 1306-P, 1563-P, 1649-P, 1658-P, 1668-P, IRF3 1912-P Klotho 557-P, 2293-P 1764-P, 1766-P, 1776-P, 1835-P, 1842-P, 1877-P, Irisin 58-OR, 100-OR, 151-OR, 1450-P, 1767-P, Knockout mice 40-OR, 518-P 1887-P, 1921-P, 1931-P, 1937-P, 1938-P, 1946-P, 1942-P, 2013-P, 2885-PO Knowledge attitudes 1646-P 1955-P, 1974-P, 1996-P, 2005-P, 2019-P, 2022-P, Iron 1361-P, 2204-P Koreans 1641-P 2059-P, 2146-P, 2482-PO Iron accumulation 1777-P L cell 1087-P Insulin sensitizers 30-OR, 1076-P, 1787-P, 2195-P IRS1 226-OR, 1790-P, 1809-P, 1820-P Laboratory sample handling 895-P Insulin sensitizing action 1905-P IRS2 225-OR Lactate 231-OR, 1922-P, 2899-PO, 2901-PO Insulin signaling 224-OR, 726-P, 1796-P, 1806-P, Ischemia 1187-P Lactose 1530-P 2094-P, 2259-P, 2836-PO, 2838-PO Ischemia reperfusion 508-P LADA 1464-P Insulin signaling cascade 1812-P Islet 136-OR, 300-OR, 339-OR, 341-OR, 1624-P, Laminin 2206-P Insulin signaling defects 496-P 1722-P, 1740-P, 1915-P, 2040-P, 2080-P, 2179-P, Laparoscopic banding 2116-P, 2944-PO Insulin stability 2580-PO 2185-P, 2189-P, 2197-P, 2197-P, 2214-P, 2233-P, Laparoscopic sleeve gastrectomy 2004-P Insulin synthesis 2200-P 2234-P, 2245-P, 2251-P, 2270-P, 2827-PO, LAPSCOVERY technology 950-P Insulin therapy 173-OR, 476-P, 690-P, 705-P, 879-P, 2897-PO Large-for-gestational age infants 1390-P 1146-P, 1224-P, 2758-PO, 2877-PO Islet adaptation 2272-P Latent autoimmune diabetes 1107-P, 1715-P Insulin transcription 370-OR Islet allorejection 1725-P Latino 307-OR, 834-P Insulin trans-endothelial transport 1805-P, Islet amyloid 2162-P, 2171-P Latino glycemic control 1474-P 1817-P Islet autoantibodies 246-OR, 248-OR, 1831-P LDL 660-P Insulin treatment 310-OR, 812-P, 929-P, 2975-PO Islet autoimmunity 286-OR, 350-OR, 1530-P, 1609-P, LDL particle 2413-PO, 2426-PO Insulin use 1246-P 1629-P LDL receptor knock-out 656-P Insulinogenic index 2850-PO Islet autotransplant 358-OR LDL-C goal 1504-P Insulin-on-board 998-P Islet beta cell 1737-P, 2273-P, 2274-P LDL-cholesterol 659-P Insulitis 1686-P Islet biology 2244-P Learning style 2448-PO Insupad 965-P Islet cells 1840-P Left ventricular diastolic dysfunction 2003-P Intact proinsulin 1117-P, 2213-P, 2213-P Islet compensatory response 2191-P Left 2032-P Integrin 1870-P, 2061-P Islet dysfunction 1852-P, 2161-P Leg Length 1578-P Intensified 651-P Islet endothelial cells 2185-P Legacy effect 2975-PO Intensive glycemic control 1404-P Islet function 153-OR, 1638-P, 1850-P, 2849-PO Length of gestation 1368-P

A764 OR-Oral P-Poster PO-Published Only Length of hospital stay 1477-P, 2317-PO 916-P, 941-P, 1008-P, 1021-P, 1038-P, tolerance test 748-P, 989-P, 1490-P 37-OR, 147-OR, 1668-P, 1762-P, 1838-P, 1047-P, 1048-P, 1189-P, 2594-PO Mealtime insulin dose 915-P 1965-P, 2012-P, 2048-P, 2105-P, 2179-P, 2686-PO 1099-P Mean amplitude of glycemic excursions 1058-P Leptin antagonist 623-P Local immunosuppression 1725-P Measurement 821-P Leptin resistance 2051-P Long acting dual agonist 1041-P Mechanical stress 1761-P Leptin sensitivity 2085-P Long acting oxyntomodulin 1041-P Mechanistic target of rapamycin 1806-P Leukotrienes 615-P Long term cure 2205-P Media 2454-PO LF/HF ratio 2151-P, 2314-PO Long-acting insulin 950-P Medial calcification 2326-PO, 2341-PO L-FABP 2381-PO Longevity 2054-P Medical cost 2439-PO Lifestyle 1661-P, 1953-P, 2147-P, 2513-PO Longitudinal 1610-P, 1660-P Medical nutrition therapy 1526-P SUBJECT INDEX Lifestyle behaviors 2468-PO Long-term 67-OR, 263-OR Medical students 2513-PO Lifestyle changes 2441-PO Losartan 1970-P Medicare 262-OR, 274-OR, 1236-P, 1269-P, 1278-P, Lifestyle changes in youth 2516-PO Loss of function coding variants 324-OR 2777-PO Lifestyle intervention 78-OR, 305-OR, 381-OR, Loss of productivity 2661-PO Medication 2121-P 740-P, 746-P, 1221-P, 2929-PO Lost to follow up 2667-PO Medication adherence 782-P, 783-P, 836-P, 1250-P, Lifestyle modification 703-P Low birth weight 1826-P, 2089-P 1253-P, 1270-P, 1285-P, 1439-P, 2926-PO Limb ischemia 668-P Low carbohydrate diet 756-P, 763-P, 1816-P Medication costs 1255-P 299-OR, 374-OR, 375-OR, 376-OR, Low glucose suspend 228-OR, 876-P Medication error 275-OR 1091-P, 1093-P, 1096-P, 1117-P, 1138-P, 1159-P, Low index diet 776-P Medication initiation 1253-P 1177-P, 1183-P, 1200-P, 2358-PO Low intensity vibrations 723-P Medication nonadherence 209-OR Linkage 1396-P Low literacy 693-P, 2457-PO Medication protocol 2464-PO Lipase 1957-P Low protein diet 169-OR MEK/ERK 2842-PO Lipid 270-OR, 640-P, 1773-P, 1976-P Low testosterone 1502-P 199-OR Lipid accumulation 1965-P Lower extremity 120-OR Membrane fusion 222-OR Lipid and glucose metabolism 22-OR, 90-OR Lower extremity arterail disease 436-P Menarche 1438-P Lipid droplet 466-P, 2862-PO Lower-extremity amputations 670-P Mendelian randomization 446-P Lipid genetics 327-OR Low-grade inflammation 141-OR Menopause 1438-P, 1568-P Lipid infusion 1775-P LP-PLA2 987-P Mental health problems 2506-PO, 2948-PO Lipid mediated developmental programming Lung dysfunction 2722-PO Mesenchymal stem cells 723-P, 2832-PO 267-OR LY2405319 1019-P Messengers 2976-PO Lipid metabolism 521-P, 522-P, 1653-P, 1913-P, Lymphocytes B 2823-PO Meta-analysis 81-OR, 122-OR, 127-OR, 347-OR, 2113-P, 2336-PO Lymphoid stroma 1723-P 1047-P, 1063-P, 1114-P, 1171-P, 1491-P, 1536-P, Lipid profile 1592-P Lysosome 639-P 1537-P, 1560-P, 1567-P, 1577-P, 2535-PO Lipid-lowering therapy 2412-PO Macronutrients 35-OR, 1537-P, 2123-P Metabalomics 2036-P Lipids 761-P, 1188-P, 1424-P, 1425-P, 2605-PO 294-OR, 466-P, 1712-P, 1721-P, 2055-P, Metabochip 1657-P Lipoatrophic diabetes 143-OR 2060-P, 2362-PO Metabolic adaptation 2139-P Lipodystrophy 147-OR, 2588-PO Macrophage activation 927-P Metabolic control 2458-PO, 2472-PO Lipogenesis 909-P, 1758-P, 1881-P 2653-PO Metabolic 1536-P, 2044-P, 2417-PO Lipohypertrophy 1212-P 449-P, 589-P, 2061-P Metabolic flexibility 2479-PO Lipolysis 1956-P, 2062-P, 2194-P Macrosomia 1378-P Metabolic insulin resistance 1939-P Lipomic profiling 2481-PO Macrovascular 346-OR, 432-P, 438-P, 497-P, Metabolic memory 105-OR Lipopolysaccharide 415-P 2334-PO, 2350-PO Metabolic pathways 2239-P Lipoprotein 298-OR, 332-OR, 456-P, 641-P, 644-P, Macrovascular events 344-OR Metabolic regulator 1019-P 662-P, 1161-P Maf 2293-P Metabolic signaling and insulin secretion 2262-P Lipotoxic apoptosis 2174-P Magnetic resonance imaging 49-OR Metabolic surgery 2090-P Lipotoxicity 366-OR, 639-P, 1865-P, 2188-P, 2230-P, Magnetic resonance spectroscopy 259-OR 420-P, 456-P, 459-P, 464-P, 2281-P, 2284-P Malnutrition 2743-PO 474-P, 484-P, 487-P, 608-P, 736-P, 745-P, 746-P, 65-OR, 359-OR, 505-P, 1005-P, 1007-P, Management 869-P, 1219-P 758-P, 813-P, 1297-P, 1427-P, 1501-P, 1515-P, 1028-P, 1039-P, 1153-P, 1731-P, 2073-P, 2284-P, Management of diabetes in Ccina 2663-PO 1528-P, 1539-P, 2038-P, 2058-P, 2071-P, 2082-P, 2591-PO, 2592-PO, 2604-PO, 2605-PO, 2609-PO, MAPK 2290-P 2112-P, 2126-P, 2152-P, 2338-PO, 2474-PO, 2610-PO, 2897-PO Marathon 2483-PO 2728-PO, 2736-PO, 2739-PO, 2775-PO, 2952-PO Liraglutide, type 2 diabetes mellitus, 2603-PO MARD 883-P, 891-P Metabolic traits 735-P Lisofylline 1207-P Marine ω3FA 2423-PO Metabolically healthy obese 2097-P, 2126-P, Literacy and numeracy sensitive diabetes education Married couples 2441-PO 2950-PO 2457-PO Mass 2169-P Metabolism 771-P, 1312-P, 1677-P, 1682-P, 1772-P, Live 2487-PO Mass spectrometry 221-OR, 2837-PO 1783-P, 1785-P, 1793-P, 1926-P, 1949-P, 2065-P, Liver 328-OR, 640-P, 1683-P, 1867-P, 1868-P, 1885-P, Mass spectrum 2908-PO 2223-P, 2237-P, 2478-PO, 2866-PO 1910-P, 1921-P, 2865-PO Maternal age 1398-P Metabolome analysis 577-P Liver 2475-PO Maternal diabetes 44-OR Metabolomics 59-OR, 213-OR, 1125-P, 1782-P, Liver fat 216-OR, 1290-P, 1862-P, 1877-P, 2022-P Mathematical model 573-P, 1791-P, 2881-PO, 2156-P, 2212-P, 2837-PO Liver fibrosis 1866-P, 2092-P 2976-PO Metabonomics 516-P Liver inflammation 1866-P Matrix-metalloproteinases 476-P Metallothionein 431-P Liver injury 2861-PO Matsuda index 2950-PO Metanalysis 939-P Liver lipogenesis 1907-P Maximum weight 1431-P Metastatic nasopharyngeal carcinoma 1553-P Liver metabolism 1897-P MCP-1 1126-P Meteorological parameters 1598-P Liver mitochondrial function 2108-P MDI 691-P, 872-P, 875-P, 877-P, 885-P, 889-P, 894-P, Meter downloads 781-P Liver steatosis 1880-P 906-P Metformin 69-OR, 281-OR, 385-OR, 457-P, 665-P, Liver transaminase 1600-P Meal detection 2577-PO 1052-P, 1062-P, 1068-P, 1093-P, 1095-P, 1119-P, Liver transplantation 2829-PO, 2831-PO Meal related glucose challenge 907-P 1129-P, 1147-P, 1184-P, 1428-P, 1514-P, 1645-P, Liver, glucose-response 1899-P Meal replacement 768-P 1651-P, 1667-P, 1906-P, 2045-P, 2138-P, 2633-PO, Living alone 828-P Meal timing 1528-P, 1529-P 2636-PO, 2649-PO, 2783-PO

OR-Oral P-Poster PO-Published Only A765 Metformin extended release 1289-P Monkey 1003-P Naltrexone bupriopion 232-OR, 1056-P, 1130-P, Metformin plus 1883-P Monocyte 377-OR, 483-P, 1631-P, 1703-P, 2353-PO 1149-P Methylation 1648-P, 2247-P Monofilament 56-OR Nano medicine 2708-PO Methylglyoxal 609-P, 2721-PO Monogenic 1628-P, 1639-P, 2204-P, 2810-PO Nanoencapsulation 1728-P Methylmalonic acid 1068-P Monogenic diabetes 353-OR, 663-P, 1671-P Napping 1599-P Metric 691-P Monotherapy 1085-P, 1105-P Naringenin 2878-PO Mexican 1392-P, 2778-PO Morbid obesity 400-P, 1049-P, 2115-P, 2603-PO Nascent metabolic syndrome 434-P Mhealth 1308-P Morning blood pressure surge 467-P NASH 1885-P, 2067-P Mice 1742-P, 2975-PO Mortality 56-OR, 82-OR, 180-OR, 184-OR, 410-P, Native americans 1503-P SUBJECT INDEX Micro RNA 1743-P 412-P, 435-P, 480-P, 727-P, 818-P, 1226-P, 1403-P, Natriuretic peptide receptors 2110-P Microalbuminuria 566-P, 1520-P, 2345-PO 1422-P, 1426-P, 1473-P, 1499-P, 1500-P, 1538-P, Natural compounds 2418-PO Microaneurysms 154-OR 1549-P, 1551-P, 1564-P, 1601-P, 1603-P, 1604-P, Neck circumference 1427-P, 1453-P Microangiopathy 383-OR, 560-P, 634-P, 794-P 1608-P, 1732-P, 2096-P, 2122-P, 2142-P, 2729-PO, Negative affect 795-P Microarray 2858-PO 2749-PO, 2766-PO, 2781-PO Negative thyroid antibody 2731-PO Microbiota 2084-P Motivation 740-P Neighborhood 1562-P Microcirculation 1191-P Motivational interviewing 6-OR, 1327-P Neointima formation 499-P Microct 664-P Mouse model 1189-P, 1643-P, 1664-P, 1673-P, Neonatal birth weight 2690-PO Micro-dose 1015-P 2917-PO Neonatal diabetes 353-OR, 1626-P, 2190-P, 2223-P, Microparticles 359-OR, 2232-P, 2908-PO MRI 469-P, 2329-PO 2684-PO Microrna 145-OR, 200-OR, 291-OR, 721-P, 1692-P, MRTF-SRF 2075-P Neonatal intensive care unit 2747-PO 1817-P, 2164-P, 2216-P, 2261-P, 2265-P, 2362-PO, Mscs 1736-P, 2187-P Neonatal morbidity 1442-P 2800-PO, 2860-PO, 2918-PO MTNR1B 1652-P Neph1 2215-P Microvascular 1206-P, 1970-P Mtor 1784-P, 2262-P, 2281-P Nephrin 2215-P Microvascular blood flow 1977-P Mtor-STAT3 2902-PO Nephropathy 524-P, 525-P, 530-P, 533-P, 550-P, Microvascular complications 549-P, 863-P, 1330-P, Mtot 30-OR 553-P, 555-P, 558-P, 564-P, 571-P, 701-P, 2375-PO, 2350-PO Muller cells 159-OR 2378-PO, 2382-PO Microvascular perfusion 1951-P Multicenter, randomized, open-label, clinical trial Nerve conduction velocity 674-P, 2399-PO Microvascular recruitment 34-OR 1156-P, 1175-P Nerve degeneration 596-P Microvasculature 33-OR, 1936-P, 1964-P Multicultural 687-P Nesfatin-1 2043-P, 2902-PO Middle east and north africa 2769-PO Multidisciplinary team approach 2450-PO Net reclassification improvement 1563-P MIF 1187-P Multidrug and toxin extrusion 1(MATE1) 1052-P Network 525-P Military 2707-PO Multi-ethnic 1632-P Neural tube defects 1354-P MIN6 cells 2967-PO Multifactorial intervention 548-P Neurodegenertion 609-P Mindful eating 2453-PO Multigenerational 2066-P Neuroendocrine 1172-P, 1193-P, 2039-P Minorities 1261-P Multi-injection port 2597-PO Neuroimaging 805-P, 2111-P Minority adults 784-P Multilevel interventions 850-P Neuronal 2875-PO Mir-195 158-OR Multiple biomarkers 2098-P Neuronostatin 2286-P Mir-338-3p 195-OR Multiple daily insulin injections 872-P Neuropathy 55-OR, 56-OR, 120-OR, 558-P, 579-P, Mirna 61-OR, 1186-P Multi-trait 1634-P 587-P, 589-P, 591-P, 597-P, 608-P, 2377-PO Mirna200 1623-P Multivariate analysis 960-P Neurovascular unit 613-P Missing data 1565-P Munc18b 1833-P /lymphocyte ratio 2344-PO Mitochondria 25-OR, 28-OR, 29-OR, 721-P, 1685-P, Murine aortic endothelial cells (MAEC) 495-P New insulin delivery system 980-P 1768-P, 1770-P, 1867-P, 1890-P, 1897-P, 1898-P, Murine insulin 2 2068-P New onset type 1 diabetes 1318-P, 2682-PO 1938-P, 1954-P, 1968-P, 1969-P, 1973-P, 2043-P, Muscle 1050-P, 1933-P, 1949-P, 1967-P, 1971-P, New onset type 2 diabetes 2552-PO 2043-P 1977-P, 1982-P, 2062-P, 2127-P NEW2D 2701-PO Mitochondrial 26-OR, 292-OR, 1958-P Muscle atrophy 1947-P, 1959-P, 1975-P Newly diagnosed diabetes 928-P, 1020-P, 1030-P, Mitochondrial biogenesis 60-OR, 440-P, 2070-P Muscle cells 2836-PO 1481-P, 2346-PO, 2352-PO, 2355-PO, 2357-PO Mitochondrial DNA 582-P Muscle glucose transport 718-P Next generation sequencing 323-OR Mitochondrial dynamics 1770-P Muscle insulin resistance 1950-P Nfkb 718-P Mitochondrial dysfunction 582-P, 2063-P Muscle microvascular recruitment 1935-P NF-κb 536-P, 2175-P Mitochondrial function 35-OR, 1914-P, 1943-P, Muscle mitochondrial function 1775-P NHANES 626-P, 1459-P 1962-P Muscle specific alfa2 dead AMPK mice 796-P, 2896-PO Mitochondrial metabolism 1094-P, 1781-P 1780-P Nighttime sleep 1599-P Mitochondrial pyruvate carrier 1768-P, 1922-P Muscle steatosis 1980-P NIK 1866-P Mitofusin 2 1878-P, 1940-P Muscle strength 1403-P, 1508-P Nitric oxide 450-P, 493-P, 498-P, 624-P, 720-P, Mitophagy 1958-P Muscle transcripts 1195-P 1805-P, 2063-P, 2173-P, 2279-P MMP-9 2167-P Muscular electro-stimulation 2482-PO Nitrosative stress 18-OR MMTT 251-OR Mutation 1670-P, 2821-PO Nitrotyrosine 568-P Mobile 694-P Myocardial 2322-PO NMR 1911-P, 2413-PO Mobile health 837-P, 2474-PO Myocardial infarction 428-P Nocturnal hypoglycemia 388-P, 915-P, 934-P, 984-P Mobile phone 2679-PO Myocardium 724-P Nocturnin 2958-PO Mobile technology 2545-PO Myokine 1450-P, 1942-P, 1944-P, 1961-P, 1963-P NOD Mice 1705-P, 1711-P, 2229-P Model predictive control 16-OR, 967-P Myotube 1969-P, 2834-PO NODAT 2610-PO Model-free 998-P Myths 2466-PO Non invasive glucose monitoring 893-P Modeling 1547-P N-3 PUFA 430-P, 750-P, 761-P Nonalcoholic fatty liver 1418-P, 2785-PO Moderate exercise 730-P, 733-P Na channel blocker 924-P, 1086-P Nonalcoholic fatty liver disease 429-P, 468-P, Modification 301-OR N-acetylcysteine 526-P 1037-P, 1225-P, 1641-P, 1829-P, 1891-P, 1909-P, MODY 1639-P, 1670-P, 1671-P, 2529-PO, 2805-PO, NADPH oxidase 610-P, 2165-P, 2278-P 2414-PO, 2862-PO 2810-PO NAFLD 193-OR, 648-P, 654-P, 1169-P, 1185-P, Non-alcoholic steatohepatitis 1856-P Molecular adaptor 142-OR 1305-P, 1861-P, 1862-P, 1873-P, 1875-P, 1886-P, Non-aqueous 402-P Monitoring 1405-P 1896-P, 1902-P, 1912-P, 2857-PO Non-clinical 1024-P, 2184-P

A766 OR-Oral P-Poster PO-Published Only Non-critical care setting 261-OR Obesity-resistant 2065-P Oxyntomodulin 186-OR, 1990-P Non-critically ill 399-P, 932-P Observational study 2300-PO Oxytocin 2031-P Non-diabetic humans 1990-P Obstructive sleep apnea 568-P, 1302-P, 1443-P P38 MAPK 200-OR, 1874-P, 2366-PO Nondiabetic zucker rats 2090-P Obstructive sleep apnea syndrome 2782-PO P53 1975-P Nonhuman primate model of T2DM 2161-P Occlusion detection 975-P P70s6k1 activation 1354-P Non-human primates 1025-P, 1796-P, 1974-P Occupational health care 2137-P P8 290-OR Non-ICU patients 2301-PO Octogenarians 1095-P P85 1790-P Noninvasive 1440-P Offload 121-OR PACIC 1218-P Non-obese 1119-P Offspring BMI 77-OR Pacific islanders 2929-PO Non-whites 1714-P O-glcnac 1889-P, 1917-P PAI-1 inhibitor 1749-P SUBJECT INDEX Normal glucose tolerance 1832-P OGTT 1448-P, 1456-P, 2702-PO, 2711-PO Pain 580-P, 2533-PO Normal weight 2735-PO Older adults 390-P, 2558-PO, 2694-PO PAK1 1892-P NOS 92-OR Older patients 2695-PO Palmitate 197-OR, 490-P, 506-P, 645-P, 1784-P, Notch 1621-P Older person 2317-PO 1967-P, 2290-P, 2921-PO Novel agents 112-OR Older rural adults 852-P Palmitic acid 639-P Novel basal 912-P, 913-P, 915-P, Oleanolic acid 526-P Panax notoginseng 1140-P 917-P, 931-P Omega 3 fatty acids 415-P, 2675-PO Pancreas 1689-P, 2192-P, 2798-PO Novel methodologies 1911-P Omentin 420-P, 2004-P Pancreas cancer 2905-PO Novel therapeutic oral drug 1158-P Oncostatin 2943-PO Pancreas slice 2252-P Novel type 2 diabetes therapeutics 1127-P One-stop diabetic care 1233-P Pancreas transplantation 1738-P Nox4-SOD3-PTEN pathway 224-OR Online glucose prediction 901-P Pancreatectomy 363-OR, 2199-P Npkc 1771-P Optical coherence tomography 160-OR Pancreatic agenesis, GATA6 1339-P NPY 2272-P Optical fiber sensor 177-OR Pancreatic beta cells 197-OR, 1465-P, 1554-P, NR4A3 1787-P Optimal dosing algorithm 931-P 2176-P, 2178-P, 2215-P, 2239-P, 2267-P, 2846-PO Nrf2 465-P, 553-P, 1740-P, 2170-P, 2263-P, 2271-P Oral AHA 210-OR, 1285-P Pancreatic clamp 2014-P NRS 2002 2743-PO Oral anti-diabetic agents 363-OR Pancreatic derived factor 1899-P, 2856-PO NSS NDS 2396-PO Oral antidiabetic drugs 955-P Pancreatic islets 371-OR, 2195-P, 2259-P, 2294-P, Nuclear receptors 140-OR, 529-P, 2289-P Oral calcitonin 1076-P 2965-PO Nuclear receptors and GPCR 530-P Oral contraceptives 2019-P Pancreatic stellate cell 2277-P Nucleus accumbens 845-P, 2033-P Oral disposition index 1846-P Pancreatic structure function 2922-PO Numeracy 996-P Oral fat intake 1950-P Pancreatic β cell 2209-P, 2217-P Nurse care managers 695-P Oral glucose lowering drug 2563-PO Pancreatic-derived factor 38-OR Nurse prescribing 1264-P Oral glucose tolerance test 84-OR, 1089-P, 1316-P, Pancreatitis 358-OR, 360-OR, 362-OR, 2905-PO Nurses 1198-P 1457-P, 1458-P PANDER 1984-P, 1985-P Nursing 319-OR, 403-P, 411-P Oral health 1507-P Paraganglioma 2026-P Nutrient infusion 2912-PO Oral health related quality of life 2499-PO Paraoxonase1 414-P Nutrition 710-P, 759-P, 760-P, 768-P, 770-P, 788-P, Oral hypoglycemic agents 1205-P PARD 891-P 1858-P, 1869-P, 1952-P, 2102-P Oral hypoglycemic therapy 1551-P Parental history of type 2 diabetes 1543-P Nutrition therapy 2134-P Oral insulin 1054-P Parental longevity 1412-P Nutrition therapy for type 2 diabetes 757-P Oral peptide 1081-P Parental monitoring 791-P Nutritional counseling 2453-PO Oral salmon calcitonin 114-OR Paricalcitol 534-P Nutritional education 684-P Oral squamous cell carcinoma 2718-PO Partial pancreatectomy 2275-P Nutritional intervention 748-P Oral therapies 112-OR, 549-P Participation 2444-PO Nutritional status 2112-P Oral tolerance 1700-P Particle swarm optimization 986-P OAD 1038-P Organ culture 2252-P Pathogenesis 352-OR Obese 979-P, 997-P, 2743-PO ORMD-0801 1054-P Pathogenesis of type 2 diabetes 2001-P Obese adolescents 214-OR, 1289-P, 1289-P Orthostatic hypotension 586-P Pathophysiology of obesity 1745-P Obesity 3-OR, 33-OR, 82-OR, 96-OR, 145-OR, Osteocalcin 2005-P, 2035-P, 2242-P, 2793-PO, Pathway 2131-P 181-OR, 206-OR, 212-OR, 213-OR, 215-OR, 2933-PO Patient 581-P 243-OR, 266-OR, 292-OR, 293-OR, 296-OR, Osteomyelitis 673-P, 2440-PO Patient centered care 1218-P 326-OR, 382-OR, 539-P, 608-P, 734-P, 919-P, 96-OR Patient centered medical home 695-P, 1234-P, 953-P, 1012-P, 1040-P, 1056-P, 1130-P, 1149-P, Osteoporosis 2038-P 1237-P 1287-P, 1298-P, 1309-P, 1310-P, 1312-P, 1341-P, Osteoprotegerin 481-P Patient education 853-P, 1270-P, 2444-PO 1355-P, 1356-P, 1383-P, 1419-P, 1431-P, 1591-P, Outcomes 347-OR, 811-P, 832-P, 856-P, 1194-P, Patient health questionnaire 841-P 1613-P, 1665-P, 1675-P, 1706-P, 1868-P, 1888-P, 2436-PO, 2443-PO, 2656-PO Patient led titration 940-P, 1242-P, 2302-PO, 1941-P, 1954-P, 1967-P, 1985-P, 2037-P, 2040-P, Outreach education 2442-PO 2573-PO 2042-P, 2046-P, 2047-P, 2053-P, 2053-P, 2055-P, Overnight 10-OR Patient navigation 1240-P 2056-P, 2063-P, 2076-P, 2078-P, 2079-P, 2080-P, Overnight closed-loop system 973-P Patient perception 815-P, 820-P 2082-P, 2083-P, 2089-P, 2091-P, 2094-P, 2095-P, Overnight glucose control 13-OR Patient perspective 2578-PO 2096-P, 2098-P, 2101-P, 2102-P, 2110-P, 2111-P, 77-OR, 780-P,1552-P, 2137-P, 2475-PO, Patient preference 210-OR 2120-P, 2121-P, 2123-P, 2124-P, 2129-P, 2133-P, 2478-PO, 2960-PO Patient reported outcomes 1-OR, 1027-P, 1031-P, 2134-P, 2136-P, 2138-P, 2143-P, 2144-P, 2159-P, Oxidation 303-OR, 1810-P 1334-P, 1593-P, 2298-PO 2160-P, 2236-P, 2420-PO, 2609-PO, 2673-PO, Oxidative capacity 1969-P Patient safety 1217-P 2713-PO, 2755-PO, 2784-PO, 2792-PO, 2913-PO, Oxidative stress 104-OR, 166-OR, 341-OR, 367-OR, Pax4 1100-P, 2207-P 2914-PO, 2917-PO, 2928-PO, 2930-PO, 2935-PO, 451-P, 460-P, 502-P, 614-P, 927-P, 1353-P, 1879-P, Pax6 273-OR 2937-PO, 2938-PO, 2949-PO, 2952-PO, 2954-PO, 2017-P, 2130-P, 2173-P, 2248-P, 2335-PO, PCOS 1443-P, 1529-P 2956-PO, 2958-PO, 2960-PO, 2964-PO 2431-PO, 2762-PO, 2838-PO, 2878-PO PCSK1 2320-PO Obesity adolescents 2677-PO Oximetry 630-P, 649-P PD-1 1697-P Obesity and insulin therapy 757-P Oxoglutarate receptor 1 2374-PO PDE4 inhibitor 36-OR Obesity management 2141-P, 2945-PO, 2948-PO Oxygen consumption 1337-P, 2241-P Pdx1 336-OR, 370-OR, 2294B-P Obesity treatment 2117-P Oxygen generation 1735-P Pectin 2906-PO

OR-Oral P-Poster PO-Published Only A767 Pediatric diabetes 1308-P, 1320-P, 1320-P, 1328-P Physician perceptions 2514-PO PPAR agonist 1142-P Pediatric obesity 1294-P, 2675-PO Physician prescribing behavior 1273-P PPAR delta 1918-P, 2910-PO Pediatric type 1 diabetes 1298-P, 1321-P, 1322-P Physician specialty 1245-P PPAR gamma ligands 1127-P Pediatrics 215-OR, 356-OR, 717-P, 793-P, 809-P, Physician-patient relationship 2508-PO Ppara 1757-P 851-P, 902-P, 1299-P, 1301-P, 1303-P, 1305-P, Phytochemicals 18-OR PPARG 1644-P 1315-P, 1318-P, 1326-P, 1331-P, 1335-P, 1345-P, PI3K pathway 2250-P Pparg acetylation 302-OR 1351-P, 1424-P, 1555-P, 1614-P, 1840-P, 2449-PO, PI3K/Akt 2842-PO PPAR-gamma 1136-P 2507-PO, 2681-PO PI3K-C2G and PTEN 1798-P Pparα 1905-P, 2418-PO Peer leader 680-P Pigment epithelium-derived factor 487-P, 2404-PO Pparβ/δ 2174-P SUBJECT INDEX Peer mentoring 814-P, 825-P Pioglitazone 501-P, 509-P, 611-P, 1060-P, 1066-P, Pparγ 1202-P, 2074-P Peer support 857-P, 2509-PO 1093-P, 1111-P, 1115-P, 1161-P, 1185-P, 1192-P, Practice patterns 709-P Pen 979-P, 988-P, 997-P 1811-P, 1834-P, 1885-P, 1904-P, 1974-P, 2333-PO, 1036-P, 2597-PO Perceived stress 855-P 2614-PO, 2646-PO, 2801-PO Prandial insulin 315-OR Perception of curability 2495-PO Pisum sativum 2898-PO PRAS40 226-OR Perceptions 1349-P 565-P, 661-P Preadipocytes 2833-PO Perfluoroalkyl chemicals 1424-P PKA 334-OR, 2249-P, 2285-P Preceptorship 2460-PO Performance improvement 1216-P Pkcδ 1949-P Pre-clinical 1043-P Performance management 1336-P Placenta 268-OR, 270-OR, 272-OR Preconception counseling 792-P, 1382-P Pericyte apoptosis 621-P Placental metabolism 269-OR 694-P, 715-P, 727-P, 745-P, 747-P, 780-P, Perinatal complications 1365-P Plant-based diet/ vegetarian 775-P 1012-P, 1301-P, 1313-P, 1441-P, 1461-P, 1459-P, Periodontal bacteria 1516-P Plasma 2800-PO 1561-P, 1600-P, 1828-P, 1925-P, 2115-P, 2333-PO, Periodontal disease 905-P Plasma amino acids 766-P 2337-PO, 2488-PO, 2707-PO, 2760-PO, 2837-PO Periodontal therapy 905-P Plasma glucose 1908-P Prediabetes in primary care 265-OR Periodontitis 1507-P, 1707-P, 2499-PO Platelet reactivity 393-P Prediabetes management 1234-P Perioperative 1039-P Platelet, mean platelet volume 665-P Pre-diabetic NOD mice 1696-P Peri-operative period 1275-P Platelets 2334-PO Prediction 123-OR, 128-OR, 276-OR, 1482-P Peripheral artery disease 119-OR, 632-P, 1505-P Pleiotropy 1634-P Prediction diabetes 1547-P Peripheral blood mononuclear cells 2404-PO Pluripotent stem cells 1998-P Predictive discrimination 1460-P Peripheral insulin sensitivity 1928-P PMI-5011 2259-P Predictive hypoglycemia warning 2303-PO Peripheral neuropathy 119-OR, 576-P, 674-P, 674-P, PNPLA3 2864-PO Predictive power 1299-P 2399-PO POCT-05-A 172-OR Predictor 1448-P Peripheral sympathetic nerve activity 599-P Podiatrist 1248-P Predictor analysis 1595-P Peripheral vascular disease 2436-PO Podocyte 106-OR, 519-P, 572-P, 2373-PO Predictors of efficacy 2573-PO Perivascular adipose tissue 1960-P Podometer 2480-PO Predictors of glycemic control 1614-P Perivascular fat cells 503-P Poinecaré plotting 601-P Predictors of hypoglycemia 2302-PO PERK 368-OR Point of care blood glucose 319-OR Preformance 2460-PO Permanent neonatal diabetes mellitus 2684-PO Point of care testing 870-P Pregestational diabetes 1382-P Peroxisomal biogenesis 1896-P Policy change 819-P Pregnancy 73-OR, 76-OR, 78-OR, 266-OR, 273-OR, Peroxisome proliferator receptor alpha 1778-P Poly(ADP-ribose) polymerase 1707-P 381-OR, 1355-P, 1356-P, 1370-P, 1378-P, 1381-P, Persistence and adherence 2550-PO Polycystic ovary syndrome 2609-PO, 2762-PO 1389-P, 1392-P, 2227-P, 2264-P, 2687-PO, Persistent hyperglycemia 478-P Polymorphism 2820-PO, 2822-PO 2688-PO Personal mastery 852-P Polyneuropathy 603-P Pregnancy outcomes 1371-P Personalization 1284-P Polyphenols 166-OR Premenopausal 2031-P Person-centered 2444-PO Polyunsaturated fatty acids 1321-P Premixed insulin 948-P, 2553-PO PET 760-P, 2163-P POMC neurons 2048-P Prenatal blood pressure 2690-PO PGC1α 138-OR, 1295-P, 1898-P, 2070-P Poorly controlled 1351-P Prepregnancy diabetes 1579-P, 1594-P Pharmacist 1201-P Population-based care 1228-P Prescribing safety 1264-P Pharmacodynamics 933-P, 947-P, 951-P, 1097-P, Population-based cohort study 400-P Prescription drug label 1280-P 1106-P, 1157-P Population-level 1380-P Prevalence 1522-P, 1542-P, 1549-P, 2707-PO, Pharmacoeconomics of diabetes care 1266-P Porcine Islet 1739-P 2755-PO, 2770-PO, 2771-PO, 2786-PO, 2952-PO, Pharmacoepidemiology 1551-P Portal vein 1989-P 2960-PO Pharmacogenetics 1147-P, 1651-P, 1656-P, 2811-PO Positron emission tomography 1927-P Preventable hospitalization 2752-PO Pharmacokinetic analysis 907-P Post-CABG 454-P Prevention 770-P, 1221-P, 1700-P, 2072-P, 2489-PO, Pharmacokinetics 930-P, 982-P, 1097-P, 1106-P, Post-contraction 720-P 2942-PO 1157-P Postmenopausal 439-P, 2652-PO Prevention of childhood obesity 2674-PO Phase 3 1098-P, 1164-P Post-op glucose levels 454-P Preventive care practices 1580-P Phenotypes of type 2 diabetes 1478-P Postpartum 1373-P Primary care 3-OR, 707-P, 714-P, 1272-P, 2606-PO, Phentermine and topiramate extended-release Post-partum screening 1445-P 2668-PO, 2780-PO 2103-P Postprandial 1190-P Primary care minority 826-P Phosphatidic acid 2834-PO Postprandial glucagon release 924-P Primary care physicians 2774-PO Phosphodiesterase 2285-P Postprandial glucose 162-OR, 730-P, 777-P, 1035-P, Primary care residents 716-P Phosphodisterase-5 inhibition 500-P 2594-PO, 2615-PO Primary myocyte 1930-P Phosphoenolpyruvate carboxykinase 1844-P Postprandial hyperglycemia 941-P Primary prevention 185-OR, 1244-P, 1406-P Phosphoproteomics 1982-P Postprandial hyperlipidemia 299-OR Problem areas in diabetes scale 829-P Photolabeling 1794-P Postprandial metabolism 760-P Problem solving 785-P Physical activity 74-OR, 351-OR, 728-P, 732-P, 735-P, Postprandial plasma glucose 2569-PO Probnp 344-OR 738-P, 743-P, 800-P, 1325-P, 1358-P, 1362-P, Posttranslational 301-OR Progenitor 97-OR, 2197-P 1561-P, 2477-PO, 2480-PO Post-transplantation diabetes mellitus 2389-PO Program development 814-P Physical and mental functioning 1481-P Potassium 1546-P Program with drama 696-P Physical functioning 1499-P Potassium channel gene 2683-PO Prohormone convertaze 3 1846-P Physician knowledge 683-P Power spectral analysis 2309-PO Proinflammatory cytokines 2294A-P

A768 OR-Oral P-Poster PO-Published Only Proinflammatory response 1761-P Rare and low frequency coding variants 320-OR Retinal arteriolar wall to lumen ratio 619-P Proinsulin 2236-P, 2243-P, 2280-P Rare variant 325-OR Retinoic acid 2852-PO Prolactin 1379-P, 2205-P, 2264-P Rat 2374-PO, 2912-PO Retinoic acid receptor beta 329-OR Proliferation 2411-PO, 2595-PO, 2833-PO Rate of progression 2773-PO Retinopathy 530-P, 613-P, 616-P, 617-P, 628-P, Promoter, start site 1899-P Rating of perceived exertion (RPE) 2486-PO 1434-P, 2407-PO Pro-renin receptor 2969-PO RBP4 492-P, 1680-P, 2127-P Retinopathy nephropathy cardiovascular 547-P Prospective study 344-OR, 472-P, 1369-P, 1469-P, RCT 902-P Retrospective claims database analysis 1239-P 1563-P, 2568-PO, 2604-PO Reactive dicarbonyl species 803-P Revascularization 437-P Prostate cancer 1988-P Reactive oxygen 430-P Reverse diabetes 1694-P Pro-survival secreted factors 2180-P Reactive oxygen species 1690-P, 1704-P, 1851-P, Reward 2896-PO SUBJECT INDEX Proteasome 226-OR, 2282-P 2262-P, 2278-P, 2335-PO, 2360-PO Reward motivation neural pathways 214-OR Protein inhibition 1794-P Reactivity 504-P Rheoscan 2363-PO Protein kinase C 203-OR, 491-P Real-time continuous glucose monitoring 883-P, Rhesus monkeys 2087-P Protein metabolism 750-P 2524-PO Rho 1755-P Protein phosphatase 1 regulatory subunit 1790-P, Real-world 397-P, 1029-P, 1101-P, 1152-P, 1160-P, Rhoa 580-P 2888-PO 1414-P, 2596-PO, 2668-PO, 2696-PO, 2772-PO Rho-kinase 109-OR, 515-P, 1881-P, 1906-P, 2883-PO Protein synthesis 1955-P Recent onset diabetes 1281-P Rice consumption 1527-P Proteinuria 552-P, 561-P Receptor for advanced glycation end products Risk 276-OR, 1455-P, 1548-P Proteomics 545-P, 654-P, 1973-P, 2224-P, 2280-P, (RAGE) 495-P Risk adjustment 1407-P 2862-PO, 2888-PO Recovery 2968-PO Risk asessment 822-P Protocol 2301-PO Recurrent cardiovascular events 349-OR Risk factors 578-P, 1319-P, 1410-P, 1434-P, 1481-P, Protraction mechanism 937-P Recurrent hypoglycemia 253-OR, 257-OR 1546-P, 1574-P, 2389-PO, 2410-PO, 2432-PO, Provider satisfaction inventory 1234-P Recursive models 2303-PO, 2582-PO 2440-PO P-selectin 2352-PO Redox buffering 1968-P Risk foot 2430-PO Pseudohypoglycemia 2546-PO Reducing risk of diabetes complications 689-P Risk perception 1359-P Psoriasis 1572-P Referral patterns 1741-P Risk score 102-OR, 1466-P Psychological aspects 812-P Regeneration 41-OR, 42-OR, 578-P, 678-P, 2199-P Risk staging system 2122-P Psychological well-being 820-P Regenerative medicine 576-P Rnaseq 2201-P Psychology 2502-PO Regional adiposity 774-P Rodent model of type 1 diabetes 257-OR Psychopathology 2507-PO Registry 2705-PO, 2810-PO Rods and cones 159-OR Psychosocial 789-P, 806-P, 811-P, 832-P, 843-P, Registry study 2564-PO Rolipram 36-OR 854-P, 856-P, 1298-P, 1323-P, 1323-P, 2503-PO Regression analysis 2538-PO ROS 1693-P, 2135-P Psychosocial intervention 8-OR Regulation 289-OR 1656-P, 1719-P Psychosocial predictors 833-P Regulation of energy intake 766-P Rotation 1212-P PTEN 1799-P Regulation of pparγ 1745-P Roux-en Y gastric bypass 189-OR, 443-P, 1827-P, Pulmonary blood volume 1571-P Regulatory T cells 1684-P, 2826-PO 1992-P Pulmonary function 1571-P Reinnervation 361-OR Run-to-run control 986-P Pulmonary irradiation 2917-PO Relationships 842-P Runx2 1751-P Pulse wave velocity 354-OR, 481-P, 2332-PO Relative strength index 2543-PO Rural india 2740-PO Pump 9-OR, 980-P, 983-P, 2477-PO, 2530-PO Relaxin 2076-P S6K1 1683-P Pyelonephritis 1509-P Remission 921-P, 2572-PO Safety 208-OR, 2639-PO Pyruvate carrier 30-OR Renal disease 1517-P, 1602-P Salivary biomarkers 2718-PO Pyruvate dehydrogenase kinases 27-OR Renal dysfunction 2299-PO Salivary cortisol patterns 1294-P PYY 1087-P Renal failure 102-OR Salsalate 1884-P Qtc interval 598-P, 1044-P, 2395-PO Renal fibrosis 538-P Salt 1538-P QTL mapping 1711-P Renal function 551-P, 569-P, 1508-P, 2885-PO Salvianolic acid B 590-P Qualitative 712-P, 2503-PO Renal hyperfiltration 1196-P Sarcopenia 2126-P Quality 208-OR, 1216-P, 1218-P, 1219-P, 1320-P, Renal impairment 68-OR, 1090-P, 1104-P Sarcopenic obesity 1566-P 1336-P Renal ischemia / reperfusion injury 537-P Satisfaction 804-P, 1010-P, 1243-P, 2590-PO Quality of care 839-P, 1286-P, 1334-P, 2665-PO, Renal transplantation 2389-PO Saudi 2423-PO 2691-PO Renal volume 569-P Saxagliptin 450-P, 1107-P, 1133-P, 1134-P, 1135-P, Quality of diabetes care 1247-P Renin-angiotensin system 413-P, 556-P, 557-P, 1151-P, 1174-P, 1260-P, 2615-PO, 2626-PO, Quality of glycemic control 2537-PO 2291-P 2629-PO Quality of life 1-OR, 667-P, 787-P, 809-P, 1056-P, 2643-PO Scaffold 668-P 1230-P, 2574-PO, 2623-PO, 2948-PO Reproductive health 792-P Scavenger receptor class B type I 638-P Quality of pharmacologic care 1238-P Reprogramming 1737-P, 2202-P SCD-1 gene 1923-P Questionnaire 2586-PO Rescreening 2773-PO School children 2672-PO Race 181-OR, 2866-PO Residents 714-P School health 2516-PO Race/ethnicity 85-OR, 86-OR, 1390-P,1540-P, Resistant starch 764-P Schwann cells 51-OR, 590-P, 592-P 1545-P Resistin 1480-P, 1672-P, 2032-P SCIP 2700-PO Racial differences 571-P, 1306-P, 1863-P, 2019-P Resource use 1260-P Sclerostin 633-P Racial disparities 1373-P, 1603-P Resources 211-OR Scope of practice 2464-PO Racial minority 739-P Respiratory quotient 2479-PO Score 946-P RAGE 57-OR Responder and non-responder 1064-P Screening 828-P, 1263-P, 1372-P, 1429-P, 1441-P, Ral therapy, T2D 1078-P Restenosis 2330-PO 1446-P, 1454-P, 1461-P, 1488-P, 2691-PO, Ramadan fasting 697-P, 1205-P, 1592-P Resting energy expenditure 2877-PO 2705-PO, 2714-PO Ramipril 2392-PO Resting metabolic rate 2930-PO SDF-1β 2093-P Ranibizumab 161-OR Resting-state fmri 810-P Seasonal variation 1598-P Ranolazine 922-P, 1072-P Resveratrol 99-OR, 364-OR Secondary cardiovascular prevention 425-P Rapid follow up diabetes 2666-PO Retained roots 2499-PO Secondary care 1251-P Rapid-acting Insulin 2569-PO Retina 614-P Second-phase insulin secretion 2268-P

OR-Oral P-Poster PO-Published Only A769 Secreted protein acidic and rich in cysteine 1367-P Single-walled carbon nanotube 2521-PO Spousal behaviors 830-P Secretion 1986-P Sirna 2181-P Square-wave bolus insulin 936-P Sedentary time 738-P Sirna in vivo delivery 538-P Srage 1297-P, 2146-P, 2392-PO SEIRR 224-OR SIRS 116-OR 2268-P Selective estrogen 2289-P SIRT1 31-OR, 158-OR, 329-OR, 443-P, 1197-P, SREBP-1c 2864-PO Selenoprotein P 1887-P 1880-P, 2047-P Stable coronary artery disease 459-P Self management 680-P, 704-P, 2445-PO, 2459-PO SIRT2 32-OR Stable isotope techniques 379-OR Self monitoring of blood glucose 870-P, 879-P, SIRT3 1355-P, 2217-P Stage 3 chronic kidney disease 1075-P 893-P, 1276-P, 2461-PO, 2537-PO, 2545-PO, SIRT6 2217-P Standard of care 2451-PO SUBJECT INDEX 2671-PO, 2758-PO Sirtuins 643-P 263-OR, 648-P, 651-P, 653-P, 1209-P, 1432-P, Self-care 706-P, 795-P, 1328-P Sitagliptin 71-OR, 314-OR, 373-OR, 379-OR, 565-P, 1730-P Self-esteem 848-P 1004-P, 1045-P, 1064-P, 1114-P, 1125-P, 1173-P, 652-P, 1799-P, 2412-PO Self-report 836-P, 1376-P 1260-P, 1422-P, 2630-PO, 2631-PO, 2633-PO Statistical genetics and genetic epidemiology Sensitive peripheral neuropathy 131-OR Skeletal muscle 95-OR, 1094-P, 1140-P, 1772-P, 1633-P Sensor signal attenuation 876-P 1792-P, 1801-P, 1803-P, 1804-P, 1807-P, 1929-P, Statistical process control 1247-P Sensors 2708-PO 1930-P, 1930-P, 1931-P, 1938-P, 1941-P, 1952-P, Steady of blood glucose, pregnancy outcome Sensory impairment 1587-P 1956-P, 1957-P, 1959-P, 1963-P, 1975-P, 1976-P, 2692-PO Sensory properties 765-P 1979-P, 2088-P Steady state 917-P, 926-P Septicemia 1518-P Skeletal muscle adiposity 2099-P Steatohepatitis 1865-P, 2058-P Sequencing 321-OR, 325-OR Skeletal muscle inflammation 296-OR Steatosis 1111-P, 1890-P Ser253 phosphorylation 1774-P Skeletal muscle mitochondria 1972-P Stem cells 678-P, 2135-P, 2827-PO Serine phosphorylation of IRS-1 1815-P Skin autofluorescence 560-P, 2738-PO Steroid induced hyperglycemia 2562-PO Serotonin 252-OR, 2033-P, 2227-P, 2264-P Skin intrinsic flourescence 1333-P, 1348-P Steroids 932-P Serotonin transporters 148-OR SLC12A3 (solute carrier family 12 member 3) gene Stimulated c-peptide secretion 251-OR Serum amyloid A 638-P 2385-PO Strain difference 2237-P Serum cholesterol 2412-PO Sleep 800-P, 1585-P, 2793-PO Strain imaging 2348-PO Serum immunoglobulin G 1516-P Sleep apnea 422-P, 630-P, 1521-P, 2151-P, 2950-PO Streptozotocin 1118-P, 2087-P, 2177-P Serum inflammatory markers 673-P Sleep deprivation 1849-P Stress 8-OR, 1291-P Serum osteocalcin 439-P, 2218-P Sleep duration 85-OR Stress hyperglycemia 1483-P Serum retinol binding protein 4 1766-P Sliding-scale 1198-P Stroke 1194-P, 1401-P, 1409-P, 1410-P, 1500-P Sesame and rice bran oils blend 749-P Slow release 938-P Structured education 686-P, 690-P, 704-P, 711-P, Set7/9 2175-P SMAD7 45-OR 2459-PO, 2463-PO Severe hyperglycemia 2566-PO Small fiber neuropathy 594-P, 649-P, 2400-PO Structured lifestyle intervention 1289-P Severe hypoglycemia 396-P, 416-P, 1548-P, Small molecules 19-OR, 240-OR, 282-OR, 1100-P, STZ rat 924-P 1557-P 2041-P SU 2622-PO Severe hypoglycemic event 2317-PO Small vessel disease 617-P Subclinical atherosclerosis 1306-P Severe obesity 1255-P Smartphone 910-P, 1274-P Subcutaneous adipose tissue 17-OR, 62-OR, Sevoflurane 537-P SMBG 170-OR, 692-P, 906-P 1993-P Sex hormones 1363-P, 1568-P Smoking 356-OR, 1472-P, 1495-P, 1495-P, 1765-P, Subcutaneous fat 4-OR Sex steroids 1545-P 1980-P Subcutaneous insulin absorption 966-P Sexual dysfunction 1596-P Smoking cessation 5-OR, 1581-P Subcutaneous insulin infusion 975-P SF-36 117-OR, 934-P Smooth 204-OR, 499-P, 2883-PO Subcutaneous interstitial glucose 2524-PO SFRP4 1852-P Snail 2074-P Subgroup 1035-P, 1036-P Sgk-1 1795-P SNARE 1986-P 129-OR, 236-OR, 1061-P, 1067-P, SGLT1 and SGLT2 40-OR, 230-OR, 236-OR, 239-OR, SNP 949-P, 1147-P, 1637-P, 1655-P, 1667-P, 1672-P, 1070-P, 1428-P, 2525-PO, 2630-PO, 2656-PO 240-OR, 241-OR, 242-OR, 243-OR, 522-P, 531-P, 2812-PO, 2816-PO, 2958-PO Sulforaphane 465-P 1082-P, 1085-P, 1092-P, 1102-P, 1103-P, 1104-P, Social deprivation 686-P Sulindac 1820-P 1105-P, 1116-P, 1120-P, 1131-P, 1144-P, 1188-P, Social media 781-P, 817-P, 1334-P, 2515-PO SUMO 1824-P 2349-PO, 2612-PO, 2641-PO Social stigma 831-P Sumoylation 527-P, 536-P SH2B1 194-OR, 1871-P, 2051-P Social support 307-OR, 817-P, 2462-PO Suncus murinus 2081-P Shared medical appointment 1271-P Socioeconomic factors 681-P Suprachiasmatic 2039-P SHBG 2015-P Socioeconomic impact 1235-P SUR1 2233-P Short acting insulin 2310-PO Socioeconomic position 1587-P Sural amplitude 596-P Short stature 1808-P Socioeconomic status 1562-P, 2514-PO Surgery 919-P Shotgun 545-P SOCS3 2085-P Surveillance 1576-P, 1606-P SHP-1 621-P SOD2 331-OR Survey 581-P, 849-P SHR 1180-P Soda 1858-P Survey of autonomic symptoms (SAS) score 593-P Sibling analysis 1583-P Sodium 762-P, 2746-PO Survival 159-OR Signal transducer and activator of transcription 3 Sodium channel 922-P, 1053-P, 1053-P, 1072-P Survival analysis 635-P 2364-PO Sodium glucose co-transporter 2 238-OR, 1069-P, Susceptibility loci 326-OR Signal transduction 2273-P, 2274-P, 2288-P 1074-P, 1075-P, 1077-P, 1084-P, 1098-P, 1110-P, Sweat dysfunction 594-P, 649-P Signaling 2434-PO 1122-P, 1124-P, 1139-P, 1164-P, 1196-P, 2641-PO Sweat function 2400-PO Signature 2245-P Sodium intake 1531-P, 1538-P, 2741-PO Sweet 772-P SILAC 2856-PO Soluble CD14 489-P Sympathetic activity 2314-PO Silencing therapy 655-P Soluble leptin receptor 1838-P Sympathetic nervous system 1876-P, 2059-P Silent myocardial ischemia 433-P, 442-P Somatic 125-OR Synapse 656-P Silymarin 1078-P Sono-quantified 2588-PO Syntaxin 2 369-OR Singapore chinese 1676-P Sorcs1 91-OR, 532-P Systematic review 1244-P, 1430-P, 2535-PO Single molecule imaging 220-OR South asian 1570-P, 2515-PO Systemic autoimmune disease 1718-P Single nucleotide polymorphism 455-P, 1452-P Specificity 862-P Systemic metabolism 2867-PO Single-parent status 790-P SPLA2 987-P Systolic blood pressure 241-OR, 1573-P, 2339-PO

A770 OR-Oral P-Poster PO-Published Only T cells 19-OR, 282-OR, 285-OR, 1681-P, 1685-P, Toll-like receptor 4 1695-P, 2919-PO, 2921-PO Ucoc 2238-P 1699-P Tomosyn 2269-P Ulcer 669-P, 675-P, 2438-PO T helper I cells 296-OR Total daily dose 2576-PO Ulcer development diabetes 510-P T lymphocytes 297-OR, 491-P Traditional chinese medicine 1202-P, 2648-PO Ulcer prevention 702-P T regulatory cells 244-OR, 1709-P Trafficking kinetics 1791-P Ultra fast insulin 969-P, 989-P T1D 2567-PO, 2788-PO Training 731-P, 854-P Ultrasound 1977-P T1D complications 1623-P Trajectories 80-OR Unawareness 255-OR, 408-P T1D exchange 700-P Transaldolase exchange 1882-P Undercarboxylated osteocalcin 2933-PO T1DM 232-OR, 744-P, 926-P, 947-P, 1043-P, 1118-P Transcient neonatal diabetes mellitus 2684-PO Undernutrition 2066-P T2DM 810-P, 1039-P, 1464-P, 2027-P, 2087-P, 2253-P, Transcription 1720-P, 2291-P Underserved populations 1439-P, 2442-PO SUBJECT INDEX 2340-PO, 2575-PO, 2670-PO, 2731-PO, 2739-PO Transcription factor 364-OR, 529-P, 1628-P Undertreatment 1257-P T2DM genetics 1657-P Transcriptional regulation 2864-PO Undiagnosed diabetes 828-P Tachyphylaxis 1032-P Transendothelial transport 89-OR Uninsured 2670-PO TAK-875 1165-P, 2276-P Transethnic 1640-P United arab emirates 1286-P Target glycemia hospital 342-OR Transforming growth factor 1715-P Untreated diabetes 1575-P Target tissue 285-OR Transgenic mice 1984-P2166-P Urban resource poor community 1271-P Taste 772-P, 2914-PO Transglutaminase 283-OR Uric acid 1309-P, 2357-PO Taste receptors 188-OR, 1755-P Transition 824-P, 1328-P, 1329-P, 1352-P, 2667-PO, Urinary AQP5 544-P Taste threshold 1166-P 2797-PO Urinary tract infection 1083-P, 1139-P, 1254-P, Tbc1d1 220-OR Transition of care 1217-P, 1332-P, 1340-P 1509-P, 1511-P, 2612-PO TBC1D4 1780-P Translation 124-OR, 305-OR, 1650-P, 2281-P, Urokinase plasminogen activator 1673-P T-cell 1346-P 2294A-P Usability of closed-loop systems 992-P TCF7L2 124-OR, 1650-P, 1653-P, 1664-P, 2816-PO Translational research 2807-PO Uspstf 1252-P Team care 1237-P Transmetatarsal amputation 2432-PO Utilization and outcomes 823-P Team treatment 2657-PO Transplant 136-OR, 358-OR, 1722-P, 1739-P Utilization patterns 1589-P Teasaponin 2052-P Transplantation 362-OR, 943-P, 1730-P, 2196-P, VA patients 1258-P Technology 781-P 2832-PO Vagus nerve 191-OR Technosphere insulin 982-P Treatment 1384-P, 2370-PO, 2663-PO Validation 836-P, 1380-P, 1593-P Telemedicine 7-OR, 698-P, 858-P, 1211-P, 2670-PO, Treatment alogrithms 2464-PO Validity 829-P 2681-PO Treatment dependent strip consumption 2671-PO Variations morbid obese/diabetic 1512-P Telemetric system 910-P Treatment failure 70-OR Vascular 1191-P Telephone-delivered lifestyle support 1225-P Treatment intensification 1238-P, 1258-P, 1278-P Vascular changes 2965-PO Telephonic behavioral intervention 2-OR Treatment outcome 178-OR Vascular complications 125-OR 1200-P, 2392-PO Treatment patterns 2694-PO Vascular endothelial growth factor 45-OR, 2408-PO Telomere 1173-P Treatment preference 2637-PO Vascular events 456-P Temperature and humidity 880-P Treatment resistant 2517-PO Vascular function 773-P Temporal risk 1405-P Treatment satisfaction 1242-P Vascular growth factors 2764-PO Testosterone 441-P, 1195-P, 1435-P, 1994-P, 2070-P, Trending arrows 908-P Vascular injury 612-P 2226-P Trends 1513-P, 1542-P, 1590-P, 2755-PO Vascular insulin action 1939-P Text messaging 688-P, 706-P, 837-P Triacylglyerol, proteomics 2856-PO Vascular response 375-OR TFAM 1962-P Trialnet 1317-P, 2703-PO Vascular smooth muscle cells 1779-P TGF-beta 531-P, 1754-P TRIB3 1785-P Vasoactive intestinal peptide 2258-P TGF-β 527-P Trichlormethiazide 1204-P Vasoinhibins 157-OR TGR5 2041-P 636-P, 659-P, 1432-P, 1862-P, 1867-P, Vasoreactivity 978-P Th2 IL-4 48-OR 1888-P, 1985-P VEGF 161-OR, 225-OR, 610-P, 620-P, 1186-P, 138-OR Triglyceride-to-HDL cholesterol ratio 2672-PO 2409-PO, 2469-PO Thiamine hydrocloride 1203-P Triose phosphate 1882-P Venous bicarbonate 2651-PO 1073-P, 1094-P, 1768-P, 2275-P Triple therapy 72-OR, 384-OR, 1134-P, 2630-PO Ventromedial hypothalamic nucleus (VMN) 37-OR Thigh muscle 2125-P TRP channels 2230-P Very low density lipoprotein (VLDL) 642-P Thrombosis 421-P Trpm2 2231-P Very-low-calorie diet 1812-P, 2004-P Thrombospondin-1 1754-P TRPM4 2050-P Veterans 670-P, 1504-P Thymus 1720-P, 2826-PO Ttvs 2825-PO V-Go 985-P, 2580-PO Thyroid 1002-P T-type Ca2+ channel antagonist 1908-P Viability or death response 1721-P Thyroid autoimmunity 248-OR, 1452-P 178-OR, 1713-P, 2536-PO Video game 739-P Thyroid C-cell 1008-P 949-P Videoconferencing 785-P, 2681-PO Thyroid function 2894-PO Turkish 2685-PO, 2713-PO 372-OR, 619-P, 1101-P, 1112-P, 1132-P, Thyroid-stimulating hormone 1465-P, 1758-P Twin pregnancy 1375-P 1160-P, 2213-P, 2332-PO, 2624-PO, 2696-PO, Tight glucose control 312-OR Twin study 2136-P 2699-PO, 2772-PO Tissue distribution 1024-P TXNIP 2271-P Virus 1704-P, 1721-P Tissue gene expression 1512-P Tyk2 gene knockout 1625-P Visceral 215-OR Tissue-selective estrogen complexes 2652-PO Type 1 diabetes and insulin 2367-PO Visceral abdominal fat 2112-P Titration algorithm 962-P Type 1 diabetes remission 2794-PO Visceral adipose tissue 485-P, 2152-P TLR4 1944-P, 2107-P Type 2 diabetes prevention 1225-P Visceral fat 1290-P, 1923-P, 2059-P, 2128-P TNF alpha 1692-P, 2822-PO Type 2 diabetes, diagnosis, treatment 2451-PO Visceral obesity 1451-P TNFR 542-P Type 2 diabetes-associated snps 1636-P Visfatin 1379-P, 2130-P TNFR1 108-OR Type 2 diabetic patients with hypertension 1204-P Visual acuity 160-OR Tobacco 796-P Type 2 treatment regimens 2663-PO Visual impairment 702-P, 2452-PO Toe-brachial index 588-P inhibitor 2767-PO Vitamin B12 1184-P Toenail cadmium 83-OR U500 942-P, 952-P, 2554-PO Vitamin D 350-OR, 561-P, 752-P, 1123-P, 1141-P, 2612-PO Ubiquitin 2269-P 1311-P, 1344-P, 1535-P, 1684-P, 1769-P, 2160-P, Tolerance 244-OR, 285-OR Ubiquitination 1889-P 2373-PO, 2416-PO, 2625-PO, 2763-PO, 2791-PO

OR-Oral P-Poster PO-Published Only A771 Vitamin E 1199-P, 1416-P 1210-P, 1227-P, 1243-P, 1528-P, 1537-P, 1568-P, Worksite 738-P VLDL 660-P, 1871-P, 1888-P 1759-P, 1825-P, 1825-P, 2045-P, 2073-P, 2100-P, Worksite intervention 2929-PO 1091-P 2118-P, 2124-P, 2133-P, 2491-PO, 2623-PO, Wound healing 496-P, 1186-P, 2434-PO Volatile organic compounds 881-P, 957-P 2866-PO, 2926-PO, 2933-PO, 2949-PO, 2956-PO Xanthine oxidase 516-P Volunteer 1488-P intervention 2141-P, 2945-PO Xanturenic acid 2865-PO, 2965-PO VPT 2396-PO Weight loss program 2742-PO Xenin-25 2892-PO Vulvovaginal candidiasis 1254-P Weight loss strategies 780-P 4-OR Vwf 2323-PO Weight management 2942-PO Young 2788-PO Wagner grade 2433-PO Weight reduction 7-OR, 1376-P Young adults 708-P, 834-P, 855-P, 1249-P, 1329-P, SUBJECT INDEX Waist circumference 1485-P, 2132-P Weight, waist girth 1552-P 1340-P, 2462-PO WBC 1672-P Well-being 832-P Young patient clinic 2669-PO Web-based glucose monitoring 1211-P WFS1 and T2DM 2804-PO Young women 1669-P, 2509-PO Web-based interventions 1394-P White and brown adipose tissue 143-OR Youth 217-OR, 264-OR, 802-P, 1287-P, 1297-P, Website 2455-PO Whole genome sequencing 324-OR 1300-P, 2465-PO Weight 963-P, 1612-P, 2605-PO Whole body MRI 1290-P ZDF 1086-P, 2801-PO Weight control 2134-P Wnt 1653-P, 1760-P, 2293-P Zinc 488-P, 2233-P, 2370-PO Weight control during insulin therapy 757-P Wnt/β-catenin 633-P Zinc transporter 8 1475-P, 1687-P Weight gain 1288-P, 1370-P, 1370-P, 1385-P Wolfram syndrome, brain 1630-P Znt8 2255-P Weight loss 4-OR, 79-OR, 114-OR, 206-OR, 382-OR, Women 1545-P, 2770-PO 776-P, 833-P, 1007-P, 1040-P, 1110-P, 1183-P, Women of childbearing age 1586-P

A772 OR-Oral P-Poster PO-Published Only